Patentable Subject Matter” nurture or neglect innovation? A case study based rational analysis
•
1 like•564 views
Dara Ajay (Cheers Interactive, India) Patentable Subject matter, list out the controversial inventions ineligible for patent registration. These inventions are related to genetic modification, software patents and business methods etc. which have been debated on national, international levels at various conventions. Currently, there are multiple patent litigation reported under patentable subject matter and are prosecuted with different perspectives. However, these inventions despite meeting the criteria are still been prosecuted based on patentable subject matter. The presentation would discuss some of the famous case studies in the area of genetic modification both at level of inventions and discovery. Further, more emphasis is focused toward the recent patent case on gene discovery of Myriad Patent litigations. There by address the critical question whether “patentable subject matter” is actually satisfying the current upcoming technologies assessment or acting as an impediment for future innovations. In other words, dose patentable subject matter stifle the growth of latest upcoming technologies which could emerge as future breakthrough innovations!
Report
Share
Report
Share
Download to read offline
Recommended
The Case Of Incyte Genomics
1) Incyte Genomics pursued an ambitious business model and patent strategy in the late 1990s and early 2000s that involved sequencing the human genome, patenting gene sequences, and selling subscriptions to genomic databases and licensing the patents.
2) A key part of the strategy was filing over 2,000 patent applications covering about 11,000 human gene sequences to generate licensing revenues, but this strategy faced challenges from the US Patent Office's utility requirement.
3) In 2004, Incyte abandoned its original business model and patent strategy after the US Patent Office rejected many of its patent applications for lack of demonstrating utility and specific and substantial real world use for the gene sequences.
An Exploration of Clinical Workflows in VarSeq
In this webcast, we feature several example workflows and helpful features in the VarSeq that can be used in the clinic. We discuss options for conducting a comprehensive gene panel analysis for cancer or hereditary diseases. Then we introduce an example of a single exome workflow that goes from an unfiltered VCF created by a secondary analysis pipeline to a report containing information about interesting variants. Finally, we walk through an example of a trio analysis showcasing a variety of different filter options as well as inheritance patterns. All these workflows will result in a customizable clinical report.
Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...Human Variome Project
Background: New technologies and increased competition have, and will continue to improve the cost-effectiveness of genetic testing, making genetic analysis more accessible to medical practices worldwide. However, challenges remain to establishing the validity of such tests. Moreover many patients harbor rare or novel variants and classification is likely to remain a bottleneck in broader deployment of genetic medicine.A new successful wide cross between C. cajan (L.) Millsp. and C. lanceolatus ...
Researchers successfully crossed Cajanus cajan (pigeonpea) with Cajanus lanceolatus, producing fertile hybrids. Analysis of the hybrids found both male sterile and male fertile plants. The hybrids also showed varying levels of resistance to bruchid beetles, indicating potential for pest resistance to be transferred from the wild to cultivated species. This demonstrates the value of wild relatives for broadening the genetic base of pigeonpea.
1--GMT-PRES ENGLISH-MSTR
GlobalMed Technologies has developed a treatment called PCI that uses ultraviolet irradiation of extracted blood to inactivate viruses like HIV. It has received approval to conduct clinical trials on 100 subjects in South America. The document describes GlobalMed's manufacturing of components for the PCI process and presents results from a clinical study in the Dominican Republic where PCI reduced viral loads and opportunistic infections in HIV/AIDS patients more effectively than antiretroviral drugs. GlobalMed believes its approach can significantly reduce healthcare costs for treating HIV/AIDS.
Botanic Gardens as Sentinels of Forest Health Britton
The document discusses the need for a Sentinel Plant Network to help prevent future plant diseases from being introduced and spread. It notes that many current diseases were introduced through imported nursery stock and could not be eradicated once identified. The network would involve botanical gardens monitoring plant collections for new pests and collaborating internationally to identify threats and support early detection and rapid response. Funding has been obtained to develop training modules for staff to participate in monitoring and outreach.
Oncogenicity Scoring in VSClinical
This document summarizes a presentation by Golden Helix about their VSClinical software for clinical variant interpretation and reporting. It discusses key features of VSClinical including automated scoring of variants according to ACMG/AMP guidelines, integrated clinical reporting, and customization options. It also acknowledges funding support from several NIH grants.
ClinVar: Aggregating Data to Improve Variant Interpretation - Melissa Landrum
The rate of variant discovery continues to surpass the rate of clinicalgrade interpretation. This is a challenge for precision medicine, because fast, reliable access to variant interpretations is necessary to provide well-informed and timely interpretations of test results to patients. ClinVar is a public repository for interpretations of clinical significance and functional effects of variants in any gene and for any disease. Interpretations are submitted by many sources, including clinical testing laboratories, research laboratories, locus-specific databases, expert panels, practice guidelines, as well as OMIM® and GeneReviews™. Collecting variant interpretations in ClinVar depends on integrating data from these different sources, which has several benefits. First, data integration requires standardizing the data from each source. This improves the quality of the data in ClinVar as well as in each of the individual datasets. ClinVar staff validate HGVS expressions as a routine part of ClinVar submission processing. Submitters are encouraged to use standard terms in MedGen for diseases and phenotypes. Standard terms for clinical significance are used in ClinVar when available; for example, ClinVar uses the terms recommended by ACMG to classify variants for Mendelian diseases. Secondly, ClinVar aggregates all data for a variant defined by its genomic location. Therefore, HGVS descriptions on different transcripts or on different genomic sequences can be recognized as the same variant. Thirdly, integrating data from multiple submitters allows the evidence from all sources to be pooled together. This larger collection of evidence aids the re-evaluation of variant classifications, and is especially valuable for rare variants and novel gene-disease relationships. Fourthly, data integration means that variant interpretations from different sources can be viewed together and compared. Thus a ClinVar user has access to interpretations outside any internal system and knows when there is consensus in the interpretation or not. Submitting laboratories use reports of conflicting interpretations in ClinVar to prioritize variants that they should re-evaluate. ClinVar receives data from many data providers, and therefore provides clear attribution to each contributing group, including links to records in LSDBs. Each source may update their submission to ClinVar at any time. For example, a record may be updated when a variant is re-classified or when additional evidence is available to support the interpretation. Submitters may consider providing regular updates to ClinVar to prevent their interpretations from becoming out of date. Submissions to ClinVar describe variants that range in complexity from simple alleles with explicit sequence locations through copy number changes and cytogenetic rearrangements with fuzzy boundaries.
Recommended
The Case Of Incyte Genomics
1) Incyte Genomics pursued an ambitious business model and patent strategy in the late 1990s and early 2000s that involved sequencing the human genome, patenting gene sequences, and selling subscriptions to genomic databases and licensing the patents.
2) A key part of the strategy was filing over 2,000 patent applications covering about 11,000 human gene sequences to generate licensing revenues, but this strategy faced challenges from the US Patent Office's utility requirement.
3) In 2004, Incyte abandoned its original business model and patent strategy after the US Patent Office rejected many of its patent applications for lack of demonstrating utility and specific and substantial real world use for the gene sequences.
An Exploration of Clinical Workflows in VarSeq
In this webcast, we feature several example workflows and helpful features in the VarSeq that can be used in the clinic. We discuss options for conducting a comprehensive gene panel analysis for cancer or hereditary diseases. Then we introduce an example of a single exome workflow that goes from an unfiltered VCF created by a secondary analysis pipeline to a report containing information about interesting variants. Finally, we walk through an example of a trio analysis showcasing a variety of different filter options as well as inheritance patterns. All these workflows will result in a customizable clinical report.
Establishing validity, reproducibility, and utility of highly scalable geneti...
Establishing validity, reproducibility, and utility of highly scalable geneti...Human Variome Project
Background: New technologies and increased competition have, and will continue to improve the cost-effectiveness of genetic testing, making genetic analysis more accessible to medical practices worldwide. However, challenges remain to establishing the validity of such tests. Moreover many patients harbor rare or novel variants and classification is likely to remain a bottleneck in broader deployment of genetic medicine.A new successful wide cross between C. cajan (L.) Millsp. and C. lanceolatus ...
Researchers successfully crossed Cajanus cajan (pigeonpea) with Cajanus lanceolatus, producing fertile hybrids. Analysis of the hybrids found both male sterile and male fertile plants. The hybrids also showed varying levels of resistance to bruchid beetles, indicating potential for pest resistance to be transferred from the wild to cultivated species. This demonstrates the value of wild relatives for broadening the genetic base of pigeonpea.
1--GMT-PRES ENGLISH-MSTR
GlobalMed Technologies has developed a treatment called PCI that uses ultraviolet irradiation of extracted blood to inactivate viruses like HIV. It has received approval to conduct clinical trials on 100 subjects in South America. The document describes GlobalMed's manufacturing of components for the PCI process and presents results from a clinical study in the Dominican Republic where PCI reduced viral loads and opportunistic infections in HIV/AIDS patients more effectively than antiretroviral drugs. GlobalMed believes its approach can significantly reduce healthcare costs for treating HIV/AIDS.
Botanic Gardens as Sentinels of Forest Health Britton
The document discusses the need for a Sentinel Plant Network to help prevent future plant diseases from being introduced and spread. It notes that many current diseases were introduced through imported nursery stock and could not be eradicated once identified. The network would involve botanical gardens monitoring plant collections for new pests and collaborating internationally to identify threats and support early detection and rapid response. Funding has been obtained to develop training modules for staff to participate in monitoring and outreach.
Oncogenicity Scoring in VSClinical
This document summarizes a presentation by Golden Helix about their VSClinical software for clinical variant interpretation and reporting. It discusses key features of VSClinical including automated scoring of variants according to ACMG/AMP guidelines, integrated clinical reporting, and customization options. It also acknowledges funding support from several NIH grants.
ClinVar: Aggregating Data to Improve Variant Interpretation - Melissa Landrum
The rate of variant discovery continues to surpass the rate of clinicalgrade interpretation. This is a challenge for precision medicine, because fast, reliable access to variant interpretations is necessary to provide well-informed and timely interpretations of test results to patients. ClinVar is a public repository for interpretations of clinical significance and functional effects of variants in any gene and for any disease. Interpretations are submitted by many sources, including clinical testing laboratories, research laboratories, locus-specific databases, expert panels, practice guidelines, as well as OMIM® and GeneReviews™. Collecting variant interpretations in ClinVar depends on integrating data from these different sources, which has several benefits. First, data integration requires standardizing the data from each source. This improves the quality of the data in ClinVar as well as in each of the individual datasets. ClinVar staff validate HGVS expressions as a routine part of ClinVar submission processing. Submitters are encouraged to use standard terms in MedGen for diseases and phenotypes. Standard terms for clinical significance are used in ClinVar when available; for example, ClinVar uses the terms recommended by ACMG to classify variants for Mendelian diseases. Secondly, ClinVar aggregates all data for a variant defined by its genomic location. Therefore, HGVS descriptions on different transcripts or on different genomic sequences can be recognized as the same variant. Thirdly, integrating data from multiple submitters allows the evidence from all sources to be pooled together. This larger collection of evidence aids the re-evaluation of variant classifications, and is especially valuable for rare variants and novel gene-disease relationships. Fourthly, data integration means that variant interpretations from different sources can be viewed together and compared. Thus a ClinVar user has access to interpretations outside any internal system and knows when there is consensus in the interpretation or not. Submitting laboratories use reports of conflicting interpretations in ClinVar to prioritize variants that they should re-evaluate. ClinVar receives data from many data providers, and therefore provides clear attribution to each contributing group, including links to records in LSDBs. Each source may update their submission to ClinVar at any time. For example, a record may be updated when a variant is re-classified or when additional evidence is available to support the interpretation. Submitters may consider providing regular updates to ClinVar to prevent their interpretations from becoming out of date. Submissions to ClinVar describe variants that range in complexity from simple alleles with explicit sequence locations through copy number changes and cytogenetic rearrangements with fuzzy boundaries.
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Our last webcast introduced the newest features of VarSeq that will be included in our upcoming release. After a serious developmental effort, we are excited to announce one of these being the integration of ACMG Guidelines for CNVs!
VarSeq is not only the tertiary environment to filter through your imported SNVs and indels from any VCF file, but also includes robust and proven capabilities of CNV detection and clinical variant interpretation. With our upcoming release, users will be able to leverage an automated CNV ACMG classification filter that is paired with the CNV evaluation in the VSClinical interpretation hub. This webcast will expose attendees to literature reinforcing the quality of our CNV caller, as well as showing examples of CNV analysis to demonstrate how this tool can streamline the analysis process. In this webcast, we will cover:
Describing the new CNV guidelines and how Golden Helix tackles their complexity
Assessing CNV impact on Gene and Gene Dosage
Cited literature referencing the accuracy of VarSeq’s CNV calling
Product demonstrations of VSClinical’s CNV interpretation/classification and final report functionalities
Manually traversing the guidelines and classification process is fundamentally complex with multiple criteria considerations, collecting any necessary caveats, and bulk literature review just to name a few. It is our goal to simplify and streamline this process without losing user-control of final results or overlooking any crucial criteria components necessary for final classification. We hope you will join us to see how this is accomplished as we explore the ACMG CNV Guidelines within VSClinical from the user’s perspective!
ACMG-Based Variant Classification with VSClinical
Golden Helix is a global bioinformatics company founded in 1998 that provides software for variant annotation, filtering, and interpretation. Their flagship products are VarSeq Suite and VSClinical. VarSeq Suite allows for powerful variant filtering and annotation using curated public databases and premium annotations. VSClinical streamlines variant classification using American College of Medical Genetics and Genomics guidelines through a four-phased workflow involving variant filtering, evidence assessment, classification, and reporting. It provides consistent results and reduces learning curves for users. Golden Helix has over 400 customers globally and their software is cited in thousands of peer-reviewed publications.
Next-Generation Sequencing Analysis in VSClinical
VarSeq is a tertiary analysis platform that allows users to filter and annotate NGS sequencing data to identify clinically relevant variants. Following this workflow, VSClinical can then be used to automate both germline and somatic variant analysis in accordance with the ACMG and AMP guidelines by using a variety of functional prediction models and clinical and reviewer-based annotations. Once variant or biomarker interpretations are completed, they can be rendered in a customizable clinical report and stored in an internal assessment catalog as an internal variant database repository. Together, implementation of VSClinical will promote increased lab throughput as well as accuracy and compliance with the ACMG and AMP guidelines, which in turn can save time and money. To show the capabilities of our software, this webcast will provide a demonstration of how to use VarSeq and VSClinical for the evaluation of both germline and somatic variants in accordance with the ACMG and AMP Guidelines.
In this webcast, we will cover:
- Filter logics for germline and somatic variants and selecting them into the VSClinical interface
- Capabilities of functional prediction and splice site algorithms for edge case variants
- The functionality of changing the clinically relevant transcript on variant interpretation
- Rendering a clinical report with germline and somatic variants with the inclusion of clinical trials
Export Controls and Export Control Reform - Presentation Slides
The document discusses the impact of US export control reform (ECR) on export classification. It explains key concepts under the International Traffic in Arms Regulations (ITAR) and Export Administration Regulations (EAR), including differences in how items are classified under EAR99, legacy ITAR articles, and enumerated categories. It provides examples of how specific items like guns, ammunition, and materials would be categorized. It also discusses how technical data, defense articles, foreign persons, and see-through rules are treated under ECR. Finally, it contrasts how firmware is considered under ITAR versus EAR.
Biosafety Assessment and Regulations of Gene Editing
Biosafety Assessment and Regulations of Gene Editing by Dr. Vibha Ahuja during the Regional Expert Consultation on Gene Editing in Agriculture and its Regulations Technical Session III
Annotation capabilities
VarSeq provides powerful annotation capabilities for variant analysis including gene tracks, assemblies, variant functions, frequency tracks, functional predictions, and transcript annotations. It integrates information from over 20 public databases and sources and updates annotations monthly to provide the most current clinically relevant information for researchers. By centralizing variant annotations from disparate sources, VarSeq saves customers significant time and resources compared to manual curation of this data.
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
The document describes funding that supported research conducted by Golden Helix. It lists several National Institute of General Medical Sciences grant numbers that supported the work. The principal investigator for the grants is named as Dr. Andreas Scherer, CEO of Golden Helix. It is noted that the content of any research supported by this funding is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health.
BioWorldToday03082016
Celldex reported that its phase III ACT IV trial of Rintega for glioblastoma was stopped early after a recommendation from the data safety monitoring board. The control arm performed just as well as the Rintega arm, with a median overall survival of 20.4 months for Rintega patients and 21.1 months for control patients. Celldex shares fell over 50% on the news. Company executives said they are analyzing the data to understand why the control arm performed so well but currently have no explanation. Celldex has five other active programs and sufficient cash to fund operations through 2017. Its next program to report data is varlilumab, an anti-CD27 antibody.
Whole Genome Trait Association in SVS
Golden Helix’s SNP & Variation Suite (SVS) has been used by researchers around the world to do trait analysis and association testing on large cohorts of samples in both humans and other species. As Next-Generation Sequencing of whole genomes becomes more affordable, large cohorts of Whole Genome Sequencing (WGS) samples are available to search for additional trait association signals that were not found in array-based testing. In fact, recent papers have shown that WGS analysis using advanced GREML (Genomic Relatedness Restricted Maximum Likelihood) techniques is able to outperform micro-array based GWAS methods in the analysis of complex traits and proportion of the trait heritability explained.
Our latest update release of SVS has expanded the exiting maximum likelihood and GRM methods to support these new techniques. We have also enhanced various other association testing and prediction methodologies. This webcast showcases:
- Newly supported analysis workflow for whole genome variants using LD binning and enhanced GBLUP analysis
- Enhanced gender correction using REML
- Additional capabilities for genomic prediction and phenotype prediction
We are continually improving our products based on our customer’s feedback. We hope you enjoy this recording highlighting the exciting new features and select enhancements we have made.
A data exchange format and national database for producer-recorded health eve...
There is great interest in producing dairy cows that are healthy and remain in the herd longer. Direct and indirect costs associated with disease represent a significant expense to producers, and selection for improved health may reduce these costs significantly. Genetic response to selection for improved health based upon breeding values from genetic evaluations of field-recorded traits has been well-documented. That genetic variation is not currently being directly utilized for genetic improvement. Standardized health event codes and a data exchange format (Format 6) for the collection of data from on-farm record-keeping systems are necessary for the creation of a national database for health data.
II-PIC 2017: Why did I miss that Patent? How value added databases of STN he...
Makarand Waikar (ACS International, India)
With a rapid increase in the patent and non-patent literature- there is always a chance that we miss some important patent due to the complexity with which they are being reported. This is critical in prior art, Freedom-to-Operate, Infringement searches.
In this session, we will showcase case studies on how value added databases will help identify evasive information such as incompletely defined substances, chemically modified bio-sequences, prophetic substances, Markush structures, numeric properties discussed in Patents and NPL.
Case studies will be presented using STN ®–an online platform with over 100 techno-scientific databases. Over 95% of the world’s patent applications are reviewed by patent offices that use STN.
II-PIC 22017: IP Landscape Study – Unique Execution Approach – Actionable Int...
Asish Patra (Molecular Connections, India)
IP Landscape study is integral part of any R&D planning, devising future strategy, to understand competition, assess early threat/opportunity etc. Enormous efforts and time is required to analyze large set of patents manually. It can vary from anywhere between 2000-200000 records. There are many smart tools and databases to do it automatically with generation of few dynamic charts and heat maps. However, the accuracy is not very high based on our comparative analysis.
Studies were carried out at MC, on with and without the use of automated IP tools for comparing and evaluating the accuracy. Post that, MC has designed its proprietary workflow which gives automatic tool like efficiency but with Human like quality. We apply this workflow with end objective of identifying trending/key technology, top players, key companies in each sub-technology area, top countries, various trends based on timeline etc. Overall output helps the client in getting the top view with actionable intelligence. The study can be carried out in 50-70 hours/one week time of effort irrespective of domain, without compromising on quality. Here the presenter would cover few case scenarios to showcase the unique “MC-WAY".
II-PIC 2017: Optimizing R&D strategy through organized patent database
The document discusses how companies can optimize their R&D strategy through the creation of an organized patent database. It proposes a three-pronged approach of building technology databases, conducting deep dive analyses of patents, and using the insights gathered to guide R&D decisions. This approach aims to help companies identify opportunities, threats, and areas to focus their R&D spending.
II-PIC 201: Product Presentation CAS / STN
STNext is a new browser-based version of STN that provides the same proven content and search capabilities through an intuitive interface. It offers scientific and intellectual property professionals access to CAS content, Derwent World Patents Index, and other patent and non-patent collections through an enhanced and more efficient search experience. Current STN customers can access STNext at next.stn.org using their login credentials.
II-PIC 2017: Worldwide IP activities in Green Technology
Ashok Narladkar (SABIC, India)
Recent trends in intellectual property around protecting green energy innovations are captured. Patent filing activities are collected worldwide in recent years and these activities are mapped geographically. Highlights from top active players are presented who are filing large number of patents in this technology domain and their collaborations with academics. Moreover, major economies in the world are promoting green energy innovations through reducing fees and less stringent conditions for filing patent applications. Those regional promotional activities are highlighted here, so that more and more research activities in green technology may enhance in coming future.
II-PIC 2017: Drug Discovery of Novel Molecules using Chemical Data Mining tool
Muthukumarasamy Karthikeyan (CSIR-National Chemical Laboratory, India)
Surojit Sadhu (Advent Informatics, India)
Virtual screening (VS) and chemical data extracted from evidence based sources are the backbone of computational drug discovery workflow, an indispensable component in all drug design programs. It involves a host of modelling techniques from simple similarity search methods to advanced algorithms for finding the accurate bioactive conformation of a molecule to bind to its corresponding target. Chemoinformatics supports virtual screening at multiple levels during the lead optimization stage by suggesting suitable filters for numerous screenings by utilizing the power of data integration from multiple sources and derived knowledge that is essential for decision support in drug discovery and development. It is therefore pertinent to develop tools, data and emerging methods in chemoinformatics to fully understand their role and applications in virtual screening. Recently we have developed chemical informatics tools to assist drug discovery by chemical data extraction from literature, virtual library design, analysis and screening methods on selected case studies.
II-PIC 2017: Decoding the Gray Shades of Patent White Space Analysis
Manish Sinha (Gridlogics Technologies, India)
White space mapping helps businesses discover unserved markets that hold potential but do not have any products or services yet. With patents, the goal is to find promising technology areas where patents can be filed in order to strengthen ones portfolio or purely to block others. As the practice is not new, several techniques and visualizations are being used for Patent White space analysis. Using 3D Printing as an example, this presentation will focus on pitfalls in various approaches and recommend best practices for aligning the outcome of the white space analysis to your business objectives.
II-PIC 2017: Case of Classification Codes
This document discusses patent classification codes and their use and issues. It provides examples of using classification codes to search for patents related to 3D printing. Some issues with classification codes are that different authorities use different codes, codes may not adequately represent the technology disclosed, and coding lags behind new technologies. Possible solutions proposed include using a single international classification system and improving codes to better represent invention details. The expected impacts are a fairer patent system, easier searching and analysis of patents, and fostering innovation.
II-PIC 2017: Commercialization Potential of Emerging Technologies: Insights B...
Shalu Asarikandy (Shell, India)
Monalisa Patel (Shell, India)
It is important to understand the commercialization potential of an emerging technology before taking any business decision. The degree of commercialization of a technology, especially emerging technologies can be measured based on different parameters like market information, finance, Intellectual Property. Patent information can be considered as one of the good source for assessing the level of progression of technologies from invention to commercialization phase. In this talk, different correlations based on patent bibliographic data will be presented with case studies carried out in different technology fields.
II-PIC 2017: China: Life after the Patent Tsunami
Gert Frackenpohl (Lighthouse IP, Germany)
China has grown to the largest publishing authority. However, the question has been whether this was real or inflated. As we are now starting to learn that it was in fact inflated, times will be changing. With a continuing challenge of keeping up high volumes of publications, will China now take its real position in the IP space, and start reflecting publications that really show the countries innovation skills?
Satoshi Sonoh - 2015 - Toshiba MT System Description for the WAT2015 Workshop
Satoshi Sonoh - 2015 - Toshiba MT System Description for the WAT2015 WorkshopAssociation for Computational Linguistics
Toshiba presented their machine translation system for the WAT2015 workshop. Their system uses statistical post-editing (SPE) to correct rule-based machine translation (RBMT) output. It also combines SPE and phrase-based statistical machine translation (SMT) results by reranking the merged n-best lists using a recurrent neural network language model. Evaluation showed the combined system achieved the best results on most language pairs compared to SPE and SMT individually. Analysis of system selections by the combination found it primarily chose translations from SPE.Advanced Node.JS Meetup
Writing NodeJS applications is an easy task for JavaScript developers. However, getting what is happening under the hood in NodeJS may be intimidating, but understanding it is vital for web developers.
Indeed, when you try to learn NodeJS, most tutorials are about the NodeJS ecosystem like Express, Socket.IO, PassportJS. It is really rare to see some tutorials about the NodeJS runtime itself.
By this meetup, I want to spot the light on some advanced NodeJS topics so as to help developers answering questions an experienced NodeJS developer is expected to answer. Understanding these topics is essential to make you a much more desirable developer. I want to explore several topics including the famous event-loop along with NodeJS Module Patterns and how dependencies actually work in NodeJS.
I hope that this meetup would help you to be more comfortable understanding advanced code written in NodeJS.
More Related Content
What's hot
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Our last webcast introduced the newest features of VarSeq that will be included in our upcoming release. After a serious developmental effort, we are excited to announce one of these being the integration of ACMG Guidelines for CNVs!
VarSeq is not only the tertiary environment to filter through your imported SNVs and indels from any VCF file, but also includes robust and proven capabilities of CNV detection and clinical variant interpretation. With our upcoming release, users will be able to leverage an automated CNV ACMG classification filter that is paired with the CNV evaluation in the VSClinical interpretation hub. This webcast will expose attendees to literature reinforcing the quality of our CNV caller, as well as showing examples of CNV analysis to demonstrate how this tool can streamline the analysis process. In this webcast, we will cover:
Describing the new CNV guidelines and how Golden Helix tackles their complexity
Assessing CNV impact on Gene and Gene Dosage
Cited literature referencing the accuracy of VarSeq’s CNV calling
Product demonstrations of VSClinical’s CNV interpretation/classification and final report functionalities
Manually traversing the guidelines and classification process is fundamentally complex with multiple criteria considerations, collecting any necessary caveats, and bulk literature review just to name a few. It is our goal to simplify and streamline this process without losing user-control of final results or overlooking any crucial criteria components necessary for final classification. We hope you will join us to see how this is accomplished as we explore the ACMG CNV Guidelines within VSClinical from the user’s perspective!
ACMG-Based Variant Classification with VSClinical
Golden Helix is a global bioinformatics company founded in 1998 that provides software for variant annotation, filtering, and interpretation. Their flagship products are VarSeq Suite and VSClinical. VarSeq Suite allows for powerful variant filtering and annotation using curated public databases and premium annotations. VSClinical streamlines variant classification using American College of Medical Genetics and Genomics guidelines through a four-phased workflow involving variant filtering, evidence assessment, classification, and reporting. It provides consistent results and reduces learning curves for users. Golden Helix has over 400 customers globally and their software is cited in thousands of peer-reviewed publications.
Next-Generation Sequencing Analysis in VSClinical
VarSeq is a tertiary analysis platform that allows users to filter and annotate NGS sequencing data to identify clinically relevant variants. Following this workflow, VSClinical can then be used to automate both germline and somatic variant analysis in accordance with the ACMG and AMP guidelines by using a variety of functional prediction models and clinical and reviewer-based annotations. Once variant or biomarker interpretations are completed, they can be rendered in a customizable clinical report and stored in an internal assessment catalog as an internal variant database repository. Together, implementation of VSClinical will promote increased lab throughput as well as accuracy and compliance with the ACMG and AMP guidelines, which in turn can save time and money. To show the capabilities of our software, this webcast will provide a demonstration of how to use VarSeq and VSClinical for the evaluation of both germline and somatic variants in accordance with the ACMG and AMP Guidelines.
In this webcast, we will cover:
- Filter logics for germline and somatic variants and selecting them into the VSClinical interface
- Capabilities of functional prediction and splice site algorithms for edge case variants
- The functionality of changing the clinically relevant transcript on variant interpretation
- Rendering a clinical report with germline and somatic variants with the inclusion of clinical trials
Export Controls and Export Control Reform - Presentation Slides
The document discusses the impact of US export control reform (ECR) on export classification. It explains key concepts under the International Traffic in Arms Regulations (ITAR) and Export Administration Regulations (EAR), including differences in how items are classified under EAR99, legacy ITAR articles, and enumerated categories. It provides examples of how specific items like guns, ammunition, and materials would be categorized. It also discusses how technical data, defense articles, foreign persons, and see-through rules are treated under ECR. Finally, it contrasts how firmware is considered under ITAR versus EAR.
Biosafety Assessment and Regulations of Gene Editing
Biosafety Assessment and Regulations of Gene Editing by Dr. Vibha Ahuja during the Regional Expert Consultation on Gene Editing in Agriculture and its Regulations Technical Session III
Annotation capabilities
VarSeq provides powerful annotation capabilities for variant analysis including gene tracks, assemblies, variant functions, frequency tracks, functional predictions, and transcript annotations. It integrates information from over 20 public databases and sources and updates annotations monthly to provide the most current clinically relevant information for researchers. By centralizing variant annotations from disparate sources, VarSeq saves customers significant time and resources compared to manual curation of this data.
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
The document describes funding that supported research conducted by Golden Helix. It lists several National Institute of General Medical Sciences grant numbers that supported the work. The principal investigator for the grants is named as Dr. Andreas Scherer, CEO of Golden Helix. It is noted that the content of any research supported by this funding is solely the responsibility of the authors and does not necessarily represent the views of the National Institutes of Health.
BioWorldToday03082016
Celldex reported that its phase III ACT IV trial of Rintega for glioblastoma was stopped early after a recommendation from the data safety monitoring board. The control arm performed just as well as the Rintega arm, with a median overall survival of 20.4 months for Rintega patients and 21.1 months for control patients. Celldex shares fell over 50% on the news. Company executives said they are analyzing the data to understand why the control arm performed so well but currently have no explanation. Celldex has five other active programs and sufficient cash to fund operations through 2017. Its next program to report data is varlilumab, an anti-CD27 antibody.
Whole Genome Trait Association in SVS
Golden Helix’s SNP & Variation Suite (SVS) has been used by researchers around the world to do trait analysis and association testing on large cohorts of samples in both humans and other species. As Next-Generation Sequencing of whole genomes becomes more affordable, large cohorts of Whole Genome Sequencing (WGS) samples are available to search for additional trait association signals that were not found in array-based testing. In fact, recent papers have shown that WGS analysis using advanced GREML (Genomic Relatedness Restricted Maximum Likelihood) techniques is able to outperform micro-array based GWAS methods in the analysis of complex traits and proportion of the trait heritability explained.
Our latest update release of SVS has expanded the exiting maximum likelihood and GRM methods to support these new techniques. We have also enhanced various other association testing and prediction methodologies. This webcast showcases:
- Newly supported analysis workflow for whole genome variants using LD binning and enhanced GBLUP analysis
- Enhanced gender correction using REML
- Additional capabilities for genomic prediction and phenotype prediction
We are continually improving our products based on our customer’s feedback. We hope you enjoy this recording highlighting the exciting new features and select enhancements we have made.
A data exchange format and national database for producer-recorded health eve...
There is great interest in producing dairy cows that are healthy and remain in the herd longer. Direct and indirect costs associated with disease represent a significant expense to producers, and selection for improved health may reduce these costs significantly. Genetic response to selection for improved health based upon breeding values from genetic evaluations of field-recorded traits has been well-documented. That genetic variation is not currently being directly utilized for genetic improvement. Standardized health event codes and a data exchange format (Format 6) for the collection of data from on-farm record-keeping systems are necessary for the creation of a national database for health data.
What's hot (10)
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
A User’s Perspective: ACMG Guidelines for CNVs in VSClinical
Export Controls and Export Control Reform - Presentation Slides
Export Controls and Export Control Reform - Presentation Slides
Biosafety Assessment and Regulations of Gene Editing
Biosafety Assessment and Regulations of Gene Editing
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
Evaluating Copy Number Variants with VSClinical's New ACMG Guideline Workflow
A data exchange format and national database for producer-recorded health eve...
A data exchange format and national database for producer-recorded health eve...
Viewers also liked
II-PIC 2017: Why did I miss that Patent? How value added databases of STN he...
Makarand Waikar (ACS International, India)
With a rapid increase in the patent and non-patent literature- there is always a chance that we miss some important patent due to the complexity with which they are being reported. This is critical in prior art, Freedom-to-Operate, Infringement searches.
In this session, we will showcase case studies on how value added databases will help identify evasive information such as incompletely defined substances, chemically modified bio-sequences, prophetic substances, Markush structures, numeric properties discussed in Patents and NPL.
Case studies will be presented using STN ®–an online platform with over 100 techno-scientific databases. Over 95% of the world’s patent applications are reviewed by patent offices that use STN.
II-PIC 22017: IP Landscape Study – Unique Execution Approach – Actionable Int...
Asish Patra (Molecular Connections, India)
IP Landscape study is integral part of any R&D planning, devising future strategy, to understand competition, assess early threat/opportunity etc. Enormous efforts and time is required to analyze large set of patents manually. It can vary from anywhere between 2000-200000 records. There are many smart tools and databases to do it automatically with generation of few dynamic charts and heat maps. However, the accuracy is not very high based on our comparative analysis.
Studies were carried out at MC, on with and without the use of automated IP tools for comparing and evaluating the accuracy. Post that, MC has designed its proprietary workflow which gives automatic tool like efficiency but with Human like quality. We apply this workflow with end objective of identifying trending/key technology, top players, key companies in each sub-technology area, top countries, various trends based on timeline etc. Overall output helps the client in getting the top view with actionable intelligence. The study can be carried out in 50-70 hours/one week time of effort irrespective of domain, without compromising on quality. Here the presenter would cover few case scenarios to showcase the unique “MC-WAY".
II-PIC 2017: Optimizing R&D strategy through organized patent database
The document discusses how companies can optimize their R&D strategy through the creation of an organized patent database. It proposes a three-pronged approach of building technology databases, conducting deep dive analyses of patents, and using the insights gathered to guide R&D decisions. This approach aims to help companies identify opportunities, threats, and areas to focus their R&D spending.
II-PIC 201: Product Presentation CAS / STN
STNext is a new browser-based version of STN that provides the same proven content and search capabilities through an intuitive interface. It offers scientific and intellectual property professionals access to CAS content, Derwent World Patents Index, and other patent and non-patent collections through an enhanced and more efficient search experience. Current STN customers can access STNext at next.stn.org using their login credentials.
II-PIC 2017: Worldwide IP activities in Green Technology
Ashok Narladkar (SABIC, India)
Recent trends in intellectual property around protecting green energy innovations are captured. Patent filing activities are collected worldwide in recent years and these activities are mapped geographically. Highlights from top active players are presented who are filing large number of patents in this technology domain and their collaborations with academics. Moreover, major economies in the world are promoting green energy innovations through reducing fees and less stringent conditions for filing patent applications. Those regional promotional activities are highlighted here, so that more and more research activities in green technology may enhance in coming future.
II-PIC 2017: Drug Discovery of Novel Molecules using Chemical Data Mining tool
Muthukumarasamy Karthikeyan (CSIR-National Chemical Laboratory, India)
Surojit Sadhu (Advent Informatics, India)
Virtual screening (VS) and chemical data extracted from evidence based sources are the backbone of computational drug discovery workflow, an indispensable component in all drug design programs. It involves a host of modelling techniques from simple similarity search methods to advanced algorithms for finding the accurate bioactive conformation of a molecule to bind to its corresponding target. Chemoinformatics supports virtual screening at multiple levels during the lead optimization stage by suggesting suitable filters for numerous screenings by utilizing the power of data integration from multiple sources and derived knowledge that is essential for decision support in drug discovery and development. It is therefore pertinent to develop tools, data and emerging methods in chemoinformatics to fully understand their role and applications in virtual screening. Recently we have developed chemical informatics tools to assist drug discovery by chemical data extraction from literature, virtual library design, analysis and screening methods on selected case studies.
II-PIC 2017: Decoding the Gray Shades of Patent White Space Analysis
Manish Sinha (Gridlogics Technologies, India)
White space mapping helps businesses discover unserved markets that hold potential but do not have any products or services yet. With patents, the goal is to find promising technology areas where patents can be filed in order to strengthen ones portfolio or purely to block others. As the practice is not new, several techniques and visualizations are being used for Patent White space analysis. Using 3D Printing as an example, this presentation will focus on pitfalls in various approaches and recommend best practices for aligning the outcome of the white space analysis to your business objectives.
II-PIC 2017: Case of Classification Codes
This document discusses patent classification codes and their use and issues. It provides examples of using classification codes to search for patents related to 3D printing. Some issues with classification codes are that different authorities use different codes, codes may not adequately represent the technology disclosed, and coding lags behind new technologies. Possible solutions proposed include using a single international classification system and improving codes to better represent invention details. The expected impacts are a fairer patent system, easier searching and analysis of patents, and fostering innovation.
II-PIC 2017: Commercialization Potential of Emerging Technologies: Insights B...
Shalu Asarikandy (Shell, India)
Monalisa Patel (Shell, India)
It is important to understand the commercialization potential of an emerging technology before taking any business decision. The degree of commercialization of a technology, especially emerging technologies can be measured based on different parameters like market information, finance, Intellectual Property. Patent information can be considered as one of the good source for assessing the level of progression of technologies from invention to commercialization phase. In this talk, different correlations based on patent bibliographic data will be presented with case studies carried out in different technology fields.
II-PIC 2017: China: Life after the Patent Tsunami
Gert Frackenpohl (Lighthouse IP, Germany)
China has grown to the largest publishing authority. However, the question has been whether this was real or inflated. As we are now starting to learn that it was in fact inflated, times will be changing. With a continuing challenge of keeping up high volumes of publications, will China now take its real position in the IP space, and start reflecting publications that really show the countries innovation skills?
Satoshi Sonoh - 2015 - Toshiba MT System Description for the WAT2015 Workshop
Satoshi Sonoh - 2015 - Toshiba MT System Description for the WAT2015 WorkshopAssociation for Computational Linguistics
Toshiba presented their machine translation system for the WAT2015 workshop. Their system uses statistical post-editing (SPE) to correct rule-based machine translation (RBMT) output. It also combines SPE and phrase-based statistical machine translation (SMT) results by reranking the merged n-best lists using a recurrent neural network language model. Evaluation showed the combined system achieved the best results on most language pairs compared to SPE and SMT individually. Analysis of system selections by the combination found it primarily chose translations from SPE.Advanced Node.JS Meetup
Writing NodeJS applications is an easy task for JavaScript developers. However, getting what is happening under the hood in NodeJS may be intimidating, but understanding it is vital for web developers.
Indeed, when you try to learn NodeJS, most tutorials are about the NodeJS ecosystem like Express, Socket.IO, PassportJS. It is really rare to see some tutorials about the NodeJS runtime itself.
By this meetup, I want to spot the light on some advanced NodeJS topics so as to help developers answering questions an experienced NodeJS developer is expected to answer. Understanding these topics is essential to make you a much more desirable developer. I want to explore several topics including the famous event-loop along with NodeJS Module Patterns and how dependencies actually work in NodeJS.
I hope that this meetup would help you to be more comfortable understanding advanced code written in NodeJS.
John Richardson - 2015 - KyotoEBMT System Description for the 2nd Workshop on...
John Richardson - 2015 - KyotoEBMT System Description for the 2nd Workshop on...Association for Computational Linguistics
El documento describe el sistema de traducción basado en ejemplos KyotoEBMT. El sistema utiliza análisis de dependencia tanto del idioma origen como del idioma destino y puede manejar ambigüedades en las hipótesis de traducción mediante el uso de reglas de rejilla. Los resultados oficiales del WAT2015 muestran mejoras en las métricas BLEU y RIBES con la reranqueación de traducciones, aunque la reranqueación empeora la evaluación humana para la dirección de traducción japonés-chino. El sistema KyCs231n 2017 lecture10 Recurrent Neural Networks
The document discusses recurrent neural networks (RNNs). It provides examples of applications of RNNs, such as image captioning, sentiment classification, machine translation, and video classification. RNNs can process sequential data as well as non-sequential data sequentially. The document outlines the basic structure of an RNN, including how it applies the same function and parameters at each time step. It provides illustrations of different RNN configurations, such as many-to-many, many-to-one, and one-to-many. Finally, it gives an example of applying an RNN for character-level language modeling.
Exploring Session Context using Distributed Representations of Queries and Re...
Search logs contain examples of frequently occurring patterns of user reformulations of queries. Intuitively, the reformulation "san francisco" → "san francisco 49ers" is semantically similar to "detroit" →"detroit lions". Likewise, "london"→"things to do in london" and "new york"→"new york tourist attractions" can also be considered similar transitions in intent. The reformulation "movies" → "new movies" and "york" → "new york", however, are clearly different despite the lexical similarities in the two reformulations. In this paper, we study the distributed representation of queries learnt by deep neural network models, such as the Convolutional Latent Semantic Model, and show that they can be used to represent query reformulations as vectors. These reformulation vectors exhibit favourable properties such as mapping semantically and syntactically similar query changes closer in the embedding space. Our work is motivated by the success of continuous space language models in capturing relationships between words and their meanings using offset vectors. We demonstrate a way to extend the same intuition to represent query reformulations.
Furthermore, we show that the distributed representations of queries and reformulations are both useful for modelling session context for query prediction tasks, such as for query auto-completion (QAC) ranking. Our empirical study demonstrates that short-term (session) history context features based on these two representations improves the mean reciprocal rank (MRR) for the QAC ranking task by more than 10% over a supervised ranker baseline. Our results also show that by using features based on both these representations together we achieve a better performance, than either of them individually.
Paper: http://research.microsoft.com/apps/pubs/default.aspx?id=244728
Zhongyuan Zhu - 2015 - Evaluating Neural Machine Translation in English-Japan...
Zhongyuan Zhu - 2015 - Evaluating Neural Machine Translation in English-Japan...Association for Computational Linguistics
This document evaluates various neural machine translation models for English to Japanese translation. It compares different network architectures, recurrent units, and training data configurations. Results show that soft-attention models outperformed multi-layer encoder-decoder models, and training on pre-reordered data hurt performance. Neural machine translation models tended to generate grammatically correct but incomplete translations.Cs231n 2017 lecture13 Generative Model
The document discusses generative models and summarizes three popular types: PixelRNN/CNN, variational autoencoders (VAE), and generative adversarial networks (GAN). PixelRNN/CNN are fully visible belief networks that use a neural network to model the probability of each pixel given previous pixels to explicitly define the data distribution. VAEs are variational models that learn a latent representation to implicitly define the data distribution. GANs are implicit density models that train a generator and discriminator in an adversarial manner to generate samples from the data distribution.
Deep Learning Explained
This document summarizes Melanie Swan's presentation on deep learning. It began with defining key deep learning concepts and techniques, including neural networks, supervised vs. unsupervised learning, and convolutional neural networks. It then explained how deep learning works by using multiple processing layers to extract higher-level features from data and make predictions. Deep learning has various applications like image recognition and speech recognition. The presentation concluded by discussing how deep learning is inspired by concepts from physics and statistical mechanics.
Deep Learning, an interactive introduction for NLP-ers
Deep Learning intro for NLP Meetup Stockholm
22 January 2015
http://www.meetup.com/Stockholm-Natural-Language-Processing-Meetup/events/219787462/
Deep Learning for Chatbot (3/4)
This document summarizes the key topics covered in Day 3 of a DL Chatbot seminar, including Seq2Seq models with attention mechanisms, advanced Seq2Seq architectures, and advanced attention mechanisms. The topics covered RNN encoder-decoder models, attention scoring methods, hierarchical models, personalized embeddings, copying mechanisms, bidirectional attention, self-attention models like Transformer, and various Seq2Seq implementations in PyTorch. Example papers and concepts are referenced throughout relating to sequence generation, machine translation, image captioning, and question answering.
Viewers also liked (20)
II-PIC 2017: Why did I miss that Patent? How value added databases of STN he...
II-PIC 2017: Why did I miss that Patent? How value added databases of STN he...
II-PIC 22017: IP Landscape Study – Unique Execution Approach – Actionable Int...
II-PIC 22017: IP Landscape Study – Unique Execution Approach – Actionable Int...
II-PIC 2017: Optimizing R&D strategy through organized patent database
II-PIC 2017: Optimizing R&D strategy through organized patent database
II-PIC 2017: Worldwide IP activities in Green Technology
II-PIC 2017: Worldwide IP activities in Green Technology
II-PIC 2017: Drug Discovery of Novel Molecules using Chemical Data Mining tool
II-PIC 2017: Drug Discovery of Novel Molecules using Chemical Data Mining tool
II-PIC 2017: Decoding the Gray Shades of Patent White Space Analysis
II-PIC 2017: Decoding the Gray Shades of Patent White Space Analysis
II-PIC 2017: Commercialization Potential of Emerging Technologies: Insights B...
II-PIC 2017: Commercialization Potential of Emerging Technologies: Insights B...
Satoshi Sonoh - 2015 - Toshiba MT System Description for the WAT2015 Workshop
Satoshi Sonoh - 2015 - Toshiba MT System Description for the WAT2015 Workshop
John Richardson - 2015 - KyotoEBMT System Description for the 2nd Workshop on...
John Richardson - 2015 - KyotoEBMT System Description for the 2nd Workshop on...
Exploring Session Context using Distributed Representations of Queries and Re...
Exploring Session Context using Distributed Representations of Queries and Re...
Zhongyuan Zhu - 2015 - Evaluating Neural Machine Translation in English-Japan...
Zhongyuan Zhu - 2015 - Evaluating Neural Machine Translation in English-Japan...
Deep Learning, an interactive introduction for NLP-ers
Deep Learning, an interactive introduction for NLP-ers
Similar to Patentable Subject Matter” nurture or neglect innovation? A case study based rational analysis
II-PIC 2017: Patentable Subject Matter” nurture or neglect innovation? A case...
Patentable Subject Matter” nurture or neglect innovation? A case study based rational analysis
Dara Ajay (Cheers Interactive, India)
Patentable Subject matter, list out the controversial inventions ineligible for patent registration. These inventions are related to genetic modification, software patents and business methods etc. which have been debated on national, international levels at various conventions. Currently, there are multiple patent litigation reported under patentable subject matter and are prosecuted at scientific, social and ethical perspectives. However, these inventions despite meeting the criteria of novelty, inventive step and commercial application are still been prosecuted based on patentable subject matter. The presentation would discuss some of the famous case studies in the area of genetic modification, software patents and business methods and logically compare various patent value under three special categories. Further, more emphasis is focused toward the recent patent litigation cases on genetically modified inventions in terms of plants, animals and humans. There by address the critical question whether “patentable subject matter” is actually satisfying the current upcoming technologies assessment or acting as an impediment for future innovations. In other words, dose patentable subject matter stifle the growth of latest upcoming technologies which could emerge as future breakthrough innovations!
Editas Medicine Campaign Project Paper
This document outlines a communication plan to gain government support and regulation for CRISPR gene editing technology research. The plan aims to position Editas Medicine as supporting people by expanding partnerships under government guidance. Key strategies include passing legislation for FDA oversight, increasing public support through media, and influencing researchers. Target audiences are government officials, the general public, and industry leaders. Messages focus on CRISPR's medical potential and benefits of stable, ethical research through federal backing aligned with global standards. The goal is to increase the likelihood of continued, responsible CRISPR research delivering life-changing treatments to the public.
Virginia Llera - Cómo optimizar la investigación en Enfermedades Raras
La Doctora Virginia Llera, Virginia A. Llera ofreció una conferencia el 17/09/2014 en la Fundación Ramón Areces. Llera es la Fundadora de la primera organización de Enfermedades Raras y drogas huérfanas en Latino América y Caribe, GEISER, y Presidenta del Foro Internacional, ICORD (International Conference on Rare Diseases & Orphan Drugs). Su conferencia, titulada 'Optimizando los procesos de investigación en enfermedades raras y medicamentos huérfanos', tuvo lugar dentro del ciclo sobre patologías poco frecuentes organizado por Fundación Ramón Areces en colaboración con Vall d'Hebron Institute of Research, Barcelona.
He Jiankui Affair
1. In November 2018, He Jiankui revealed that he used CRISPR gene-editing to genetically modify twin babies, Lulu and Nana, born in late 2018.
2. He claims he disabled the CCR5 gene to make the babies resistant to HIV, as their father was HIV positive. However, He failed to receive proper ethics approval and conducted unsafe and unethical human experimentation.
3. He's actions faced significant backlash from the scientific community due to violations of ethical standards and risks to human research subjects.
Patent & other IPR concerns in Pharma, Chemical, Biotech etc
This document discusses intellectual property rights (IPR) concerns regarding pharmaceutical and biotechnological research. It provides an overview of the development of biotechnology and areas of patenting. Key points include: pharmaceuticals, chemicals and biotechnology are major areas where Indian organizations have obtained patents. The criteria for an invention to be patentable in India are that it must be novel, involve an inventive step, and be capable of industrial application. Some subjects are not patentable, including methods of treatment, plants, and essentially biological processes. The document also discusses issues like evergreening, compulsory licensing, and the Indian patent office's examination of biotechnological patents.
IPR Patentability of gene AMP vs Myriad gene patenting.pptx
The document discusses the Supreme Court case Myriad Genetics v. Ambry regarding patents on the BRCA1 and BRCA2 genes. It summarizes that Myriad discovered the location and sequence of these genes linked to breast and ovarian cancer. Myriad obtained patents covering the isolated DNA and cDNA of these genes. In 2013, the Supreme Court ruled that isolated DNA is not patent eligible, but cDNA created in a lab is patent eligible. The decision narrowed the scope of gene patents but allowed patents on synthetically created DNA.
Gennaro D'Urso: PharmaDAO - The future of Medicine
Gennaro D'Urso: PharmaDAO - The future of Medicine
DAO Camp 2022
Website: https://daocamp.org
Youtube: https://www.youtube.com/channel/UCeHtPZ_ZLZ-nHFMUCXY81RQ
FB: https://www.facebook.com/DAO-Camp-102442798988862/
Priyanka pillai-Tools for rare cancer data analytics
BioGridTM is a data integration portal that curates clinical, genomic, and other health data from various sources to enable its use for research while protecting privacy. Cart-WheelTM is a rare cancer database where patients can submit information about their rare tumor to facilitate research. A researcher studying small cell-ovarian cancer could access de-identified data from BioGridTM and collaborate with Cart-WheelTM to analyze genetic pathways and design treatment plans for patients with this rare cancer type.
Drug discovery using ai
Computational approaches using AI are being used to speed up drug discovery and clinical trials in the following ways:
(1) AI is being applied to large datasets to help identify new biomarkers and repurpose existing drugs, with the global AI healthcare market expected to reach $36.1 billion by 2025.
(2) Major pharmaceutical companies are collaborating and sharing data using AI to accelerate target identification and automate molecule design.
(3) Startups are generating huge image datasets from high-throughput drug screening experiments to help identify new drug candidates in areas like oncology.
(4) AI can help improve clinical trials by identifying best patient populations, enabling dynamic trial design adjustments, and improving patient access and
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
This document discusses the case of Myriad Genetics and the controversy surrounding human gene patents. It provides background on gene patents and Myriad's patents on the BRCA1 and BRCA2 genes. The Association for Molecular Pathology sued Myriad, arguing the patents were invalid as products of nature. The court agreed the composition claims were directed to unpatentable natural phenomena, though it did not rule on constitutional questions. The document examines the conflicting ethical issues around gene patenting and licensing practices, and possible policy solutions like compulsory licensing or research exemptions.
Non animal technology the future is amazing, and animal-free. #vivisection ...
This document discusses several non-animal technologies that can be used instead of animal testing for medical research and product safety testing, including computer modeling, cell culture, microdosing, proteomics, and various brain imaging technologies. It provides examples of each technique and how they are being used and developed as alternatives to animal testing, which is described as being less accurate and predictive than these human-relevant methods. The document advocates for increased adoption of these non-animal technologies to advance medical research and testing in a human-centered manner.
Ethics and the Law - Myriad Genetics
This document discusses the case of Myriad Genetics and the ethics around patenting human genes. It summarizes that Myriad Genetics holds patents on the BRCA1 and BRCA2 genes linked to breast cancer and faces criticism for aggressively enforcing these patents. The document also summarizes a key lawsuit where a court invalidated Myriad's gene patents, finding that isolated DNA is not patentable subject matter. The document discusses ongoing debates around the ethics, impacts on research and healthcare, and potential policy solutions regarding human gene patents.
Transparency solutions ema disclosure for slide share
Protecting intellectual property while allowing for maximum use of patient level data from clinical trials for research and decision support systems.
Artificial intelligence and precision medicine does the health economist need...
On April 22, 2018, in Baltimore, we presented a workshop on the impact of artificial intelligence on healthcare. Enjoy the reading!
Bayesian Models for Chagas Disease
Oral presentation given in MEDI session at 2017 ACS in DC.
co-authors Kimberley M. Zorn, Mary A. Lingerfelt, Jair L. de Siqueira-Neto, Alex M. Clark, Sean Ekins
describes drug repurposing and machine learning - for more details see www.collaborationspharma.com
GCP For M.Pharm
The document provides an overview of Good Clinical Practice (GCP) guidelines. It discusses the history and principles of GCP, as well as the roles and responsibilities of ethics committees, investigators, and sponsors in ensuring clinical trials are conducted properly and that patient rights and safety are protected. The document also summarizes the different phases of clinical trials and essential documents required for GCP compliance.
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
This presentation introduces and discussesthe concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
It was delivered by Dr. Anthony Gill at the Pathology Horizons 2017 conference in Cairns, Australia.
introduce and discuss the concept of ‘morphologomics’ that is omics approaches critically reimagined and reappraised from the viewpoint of classic morphology.
Nw biotech fundamentals day 2 session 1 introduction
Welcome to Day 2 of the Biotech fundamentals course, recap of day 1 learnings and overview of the day’s Agenda, covering:
• Medical devices and diagnostics
• Industrial applications and CleanTech
• Aquaculture
• Agriculture
Are clinical trials in developing countries exploitative ??
Clinical trials in developing countries may exploit vulnerable populations for commercial gain. Consent is sometimes inadequate, compensation for harm is insufficient, and populations receive little benefit. Trials focus on non-communicable diseases of interest to sponsors rather than local health needs. Populations are used as low-cost "test beds" with little regard for their well-being once trials end. This raises ethical issues of unfairness and double standards similar to historical abuses.
New Drug Development Process
This document outlines the new drug development process (NDDP), including drug discovery through screening, preclinical and clinical evaluation, regulatory approval from bodies like the FDA, and ethical guidelines. It describes the stages of clinical trials from Phase I through III that assess safety, efficacy and side effects in increasing numbers of participants. The goal of the NDDP is to develop new drugs to meet unmet medical needs and obtain regulatory approval to market the drug. Ethical standards like informed consent and minimizing risk to participants are required.
Similar to Patentable Subject Matter” nurture or neglect innovation? A case study based rational analysis (20)
II-PIC 2017: Patentable Subject Matter” nurture or neglect innovation? A case...
II-PIC 2017: Patentable Subject Matter” nurture or neglect innovation? A case...
Virginia Llera - Cómo optimizar la investigación en Enfermedades Raras
Virginia Llera - Cómo optimizar la investigación en Enfermedades Raras
Patent & other IPR concerns in Pharma, Chemical, Biotech etc
Patent & other IPR concerns in Pharma, Chemical, Biotech etc
IPR Patentability of gene AMP vs Myriad gene patenting.pptx
IPR Patentability of gene AMP vs Myriad gene patenting.pptx
Gennaro D'Urso: PharmaDAO - The future of Medicine
Gennaro D'Urso: PharmaDAO - The future of Medicine
Priyanka pillai-Tools for rare cancer data analytics
Priyanka pillai-Tools for rare cancer data analytics
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Ethics and the Law: The Case of Myriad Genetics, Ethics in Patenting and Eth...
Non animal technology the future is amazing, and animal-free. #vivisection ...
Non animal technology the future is amazing, and animal-free. #vivisection ...
Transparency solutions ema disclosure for slide share
Transparency solutions ema disclosure for slide share
Artificial intelligence and precision medicine does the health economist need...
Artificial intelligence and precision medicine does the health economist need...
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Morphologomics - Challenges for Surgical Pathology in the Genomic Age by Dr. ...
Nw biotech fundamentals day 2 session 1 introduction
Nw biotech fundamentals day 2 session 1 introduction
Are clinical trials in developing countries exploitative ??
Are clinical trials in developing countries exploitative ??
More from Dr. Haxel Consult
AI-SDV 2022: Henry Chang Patent Intelligence and Engineering Management
This document describes a metadata list of patent holders in various countries and regions compiled by Muchiu (Henry) Chang. The list is sorted geographically and includes patent holder names from Canada, China, Hong Kong, Macao, Taiwan, the Middle East, and Europe between 2009-2022. Key features include Chinese-English compatibility and use of open source intelligence. The list has previously been utilized by the Region of Peel in Ontario, Canada.
AI-SDV 2022: Creation and updating of large Knowledge Graphs through NLP Anal...
Knowledge Graphs are an increasingly relevant approach to store detailed knowledge in many domains. Recent advances in NLP allow to enrich Knowledge Graphs through automated analysis of large volumes of literature, reducing a lot the efforts in traditional manual information capturing. In our presentation we report the approach taken in a project with partner Fraunhofer SCAI in the life sciences where a knowledge graph organising detailed facts about psychiatric diseases has been computed.
Information of cause-effect relations between proteins, genes, drugs and diseases has been encoded in the BEL (Biological Expression Language) and imported into a Graph database to approach an indication-wide Knowledge Graph for the selected therapeutic area. Ultimately, updating the graph will amount to just rerunning the analysis on the newly published literature.
AI-SDV 2022: The race to net zero: Tracking the green industrial revolution t...
In 2019 the UK was the first major economy to embrace a legal obligation to achieve net zero carbon emissions by 2050. More broadly, the 2021 UK Innovation Strategy sets out the UK government’s vision to make the UK a global hub for innovation by 2035 with a target of increasing public and private sector R&D expenditure to 2.4% of GDP to support the UK being a science superpower with a world-class research and innovation system.
IP rights create an incentive for R&D which ultimately leads to innovation. Analysis and insights from IP data can therefore help provide a better understanding of how the IP system is being used and where and what innovation is taking place. Research and analysis of IP data is a key input to the ongoing work of the UKIPO’s Green Tech Working Group which seeks to:
further the UK’s status as a global leader by making the UK’s IP environment the best for innovating green technology;
develop and deliver IP policies to support government’s ambition on climate change and green technologies; and
to help innovators best protect and commercialise their green tech innovations both at home and internationally.
The UKIPO has been developing a broad portfolio of ‘green’ IP analytics research. A series of patent analytics reports have been published looking at green technologies, and analysis of how the UK’s Green Channel scheme for accelerated processing of green patent applications has been conducted. Patents have been used to identify technological comparative advantage within different green technologies at a country level, and new insights uncovered by mapping green technology patents to the UN Sustainable Development Goals (SDGs). Trade mark data provides a timeliness and closeness to market factor that patent data does not, and complementary trade mark analysis of UK ‘green’ trade marks, identified using a machine learning algorithm, provides a commercialisation angle to our research.
AI-SDV 2022: Accommodating the Deep Learning Revolution by a Development Proc...
Word embeddings, deep learning, transformer models and other pre-trained neural language models (sometimes recently referred to as "foundational models") have fundamentally changed the way state-of-the-art systems for natural language processing and information access are built today. The "Data-to-Value" process methodology (Leidner 2013; Leidner 2022a,b) has been devised to embody best practices for the construction of natural language engineering solutions; it can assist practitioners and has also been used to transfer industrial insights into the university classroom. This talk recaps how the methodology supports engineers in building systems more consistently and then outlines the changes in the methodology to adapt it to the deep learning age. The cost and energy implications will also be discussed.
AI-SDV 2022: Domain Knowledge makes Artificial Intelligence Smart Linda Ander...
This document profiles Linda Andersson, the CEO of Artificial Researcher. It provides details on her background, awards, research fields, and academic merits. It then discusses how domain knowledge enables artificial intelligence systems to be smarter by allowing them to understand language and text in particular domains at a deeper level. Finally, it provides an overview of Artificial Researcher's natural language processing and text mining technologies and services for tasks like passage retrieval, ontology generation, and semantic search.
AI-SDV 2022: Embedding-based Search Vs. Relevancy Search: comparing the new w...
In 2013 we witnessed an evolutionary change in the NLP field evolved thanks to the introduction of space embeddings that, with the use of deep learning architectures, achieved human-level performances in many NLP tasks. With the introduction of the Attention mechanism in 2017 the results were further improved and, as result, embeddings are quickly becoming the de facto standards in solving many NLP problems. In this presentation, you will learn how generate and use space embedding for search purposes and provide comparison metrics to more traditional relevance-based search engines. Moreover, I will provide some initial results on a paper currently under review that provides an insight on hyperparameter tuning during the generation of embeddings.
AI-SDV 2022: Rolling out web crawling at Boehringer Ingelheim - 10 years of e...
10 years in the making. How real-world business cases have driven the development of CCC's deep search solutions, leading to the capabilities for web-crawling and delivery of targeted intelligence that helps R&D; intensive companies gain a competitive advantage.
AI-SDV 2022: Machine learning based patent categorization: A success story in...
Machine learning based patent categorization: A success story in monitoring a complex technology with high patenting activity
Susanne Tropf (Syngenta, Switzerland)
Kornel Marko (Averbis, Germany)
AI-SDV 2022: Machine learning based patent categorization: A success story in...
Machine learning based patent categorization: A success story in monitoring a complex technology with high patenting activity
Susanne Tropf (Syngenta, Switzerland)
Kornel Marko (Averbis, Germany)
AI-SDV 2022: Finding the WHAT – Will AI help? Nils Newman (Search Technology,...
It is relatively easy for a human to read a document and quickly figure out which concepts are important. However, this task is a difficult challenge for a machine. During the past few decades, there have been two main approaches for concept identification: Natural Language Processing and Machine Learning. During the early part of this century, Machine Learning made great strides as new techniques came into wider use (SVM’s, Topic Modeling, etc..). Sensing the competition, Natural Language Processing responded with deployment of new emerging techniques (sematic networks, finite state automata, etc..). Neither approach has completely solved the WHAT problem. Advances in Artificial Intelligence have the potential to significantly improve the situation. Where AI is making the most impact is as an enhancement to make Machine Learning and Natural Language Processing work better and, more importantly, work together. This presentation looks at some of this history and what might happen in the future when we blend the interpretation of language with pattern prediction.
AI-SDV 2022: New Insights from Trademarks with Natural Language Processing Al...
This document discusses using natural language processing on trademark text data to gain insights. It presents research on how trademark activity changed during COVID-19, detecting emerging trends in trademarks over time, and classifying trademarks by industry. The research uses techniques like topic modeling and deep learning classifiers to analyze trademarks and identify patterns. The analysis of trademarks can provide economic indicators and reveal where businesses are focusing their innovation and market presence.
AI-SDV 2022: Extracting information from tables in documents Holger Keibel (K...
In our customer projects involving automated document processing, we often encounter document types providing crucial data in the form of tables. While established text analytics algorithms are usually optimized to operate on running text, they tend to produce rather poor results on tables as they do not capture the non-sequential relations inside them (e.g. interpret the content of a table cell relative to its column title, interpret line breaks inside a cell differently from line breaks between cells or rows). While there are elaborate information extraction products in the market for a few highly specific types of tabular documents, there is no general approach out there. The main cause for this is the fact that table structures can be encoded by a heterogenous range of layout means (e.g. column boundaries can be signaled by lines vs. aligned text vs. white space). In this talk, we will illustrate several solutions that we have developed for a range of challenges occurring in this context, both for scanned and digitally generated documents.
AI-SDV 2022: Scientific publishing in the age of data mining and artificial i...
Most scientific journals request, that the complete set of research data is published simultaneously with the peer-reviewed paper. The publication of the research data usually is carried out as so-called "Supplementary Material", attached to the original paper, or on a "Research Data Repository". Both forms have in common, that the data is published usually unstructured and not in an uniform machine processable format. This makes its further use in electronic tools for AI or data mining unnecessarily difficult or even impossible. A concept is presented, in which the data is digitally recorded, following the principle of FAIR data, as part of the publication process. This digital capture makes the data available to the scientific community for easy use in data mining and AI tools. The data in the repository contains links to the publication to document its origin. The concept is applicable for preprints, peer-review papers, diploma and doctoral theses and is particularly suitable for open access publications. Moreover, the presentation highlights correspondent activities, which were released in scientific publications recently.
AI-SDV 2022: AI developments and usability Linus Wretblad (IPscreener / Uppdr...
This document discusses using AI tools to improve patent search and analysis. It provides metrics on how well an AI system called IPscreener can retrieve patent citations compared to examiners. The metrics show recall rates increase with longer input text and when users provide additional context. Machine translation negatively impacts performance, but the AI can help users navigate patents by selecting relevant text segments. The goal is for AI to boost innovation by improving how users search for and understand prior art.
AI-SDV 2022: Where’s the one about…? Looney Tunes® Revisited Jay Ven Eman (CE...
How do you find video when you only have sparse data? While you can wander the stacks (if you can still find open stacks) for inspiration, video either physical or digital, is difficult to discover. Wandering the virtual stacks is, well, virtually impossible. Discovery platforms on the whole have not replicated the inspirational experience of wandering the stacks.
More companies are using archivable video for internal communication of the various research projects, product developments, test results, and more that are being considered, in progress, or completed. Showing how an experiment was conducted can convey considerably more information that is very difficult to communicate via text. How do you find a company video that might be helpful for your project?
A case study is presented of the problems and the solutions that were implemented by a large, multinational chemical company. A suite of content discovery technologies was used including a video to text to tagging system connected to their documents database and automatically indexed using several chemical as well as conceptual systems (rule-based, NLP, inference engine). To build the system and support the manuscript and video submission there is a metadata extraction program which pulls and inserts the metadata into the submission forms so the author can move quickly through that process.
AI-SDV 2022: Copyright Clearance Center
Copyright Clearance Center
A pioneer in voluntary collective licensing, CCC (Copyright Clearance Center) helps organizations integrate, access, and share information through licensing, content, software, and professional services. With expertise in copyright and information management, CCC and its subsidiary RightsDirect collaborate with stakeholders to design and deliver innovative information solutions that power decision-making by helping people integrate and navigate data sources and content assets. CCC recently acquired the assets and technology of Deep SEARCH 9 (DS9), a knowledge management platform that leverages machine learning to help customers perform semantic search, tag content, and discover new insights.
AI-SDV 2022: Lighthouse IP
Lighthouse IP is the world’s leading provider of intellectual property content. The core business of Lighthouse IP is sourcing and creating content from the world’s most challenging authorities. Specialized in IP data, Lighthouse IP provides over 160 countries coverage for patents, over 200 authorities for trademarks and over 90 authorities for designs. Lighthouse IP data is available via several partners. The company is headquartered in Schiphol-Rijk in the Netherlands and has offices in the United States, China, Thailand, Vietnam, Egypt, Indonesia and Belarus. Globally a team of 150 experts works on the creation of this unique data collection.
AI-SDV 2022: New Product Introductions: CENTREDOC
CENTREDOC was created in 1964 as the technical information center of the swiss watchmaking industry. Building on a strong team of engineers, CENTREDOC now offers a complete range of services and solutions for the monitoring of strategic, technological and competitive information. CENTREDOC is also a leader in the research of patent, technical and business intelligence, and offers consulting expertise in the implementation of monitoring solutions.
AI-SDV 2022: Possibilities and limitations of AI-boosted multi-categorization...
The everyday use of AI-driven algorithms for data search, analysis and synthesis comes with important time savings, but also reveals the need to understand and accept the limitations of the technology. Practical deployments on concrete topics are inevitable to assess and manage the challenges of neuronal network based AI. A workshop report.
AI-SDV 2022: Big data analytics platform at Bayer – Turning bits into insight...
What if there was a platform where literature, conference abstracts, patents, clinical trials, news, grants and other sources were fully integrated? What if the data would be harmonized, enriched with standardized concepts and ready for analysis? After building our patent analytics platform we didn’t stop dreaming and built our big data analytics platform by semantically integrating text-rich, scientific sources. In my presentation I will talk about what we built and why we built it. And, of course, I will also address the challenges and hurdles along the way. Was it worth it and what comes next? Let’s talk about it!
More from Dr. Haxel Consult (20)
AI-SDV 2022: Henry Chang Patent Intelligence and Engineering Management
AI-SDV 2022: Henry Chang Patent Intelligence and Engineering Management
AI-SDV 2022: Creation and updating of large Knowledge Graphs through NLP Anal...
AI-SDV 2022: Creation and updating of large Knowledge Graphs through NLP Anal...
AI-SDV 2022: The race to net zero: Tracking the green industrial revolution t...
AI-SDV 2022: The race to net zero: Tracking the green industrial revolution t...
AI-SDV 2022: Accommodating the Deep Learning Revolution by a Development Proc...
AI-SDV 2022: Accommodating the Deep Learning Revolution by a Development Proc...
AI-SDV 2022: Domain Knowledge makes Artificial Intelligence Smart Linda Ander...
AI-SDV 2022: Domain Knowledge makes Artificial Intelligence Smart Linda Ander...
AI-SDV 2022: Embedding-based Search Vs. Relevancy Search: comparing the new w...
AI-SDV 2022: Embedding-based Search Vs. Relevancy Search: comparing the new w...
AI-SDV 2022: Rolling out web crawling at Boehringer Ingelheim - 10 years of e...
AI-SDV 2022: Rolling out web crawling at Boehringer Ingelheim - 10 years of e...
AI-SDV 2022: Machine learning based patent categorization: A success story in...
AI-SDV 2022: Machine learning based patent categorization: A success story in...
AI-SDV 2022: Machine learning based patent categorization: A success story in...
AI-SDV 2022: Machine learning based patent categorization: A success story in...
AI-SDV 2022: Finding the WHAT – Will AI help? Nils Newman (Search Technology,...
AI-SDV 2022: Finding the WHAT – Will AI help? Nils Newman (Search Technology,...
AI-SDV 2022: New Insights from Trademarks with Natural Language Processing Al...
AI-SDV 2022: New Insights from Trademarks with Natural Language Processing Al...
AI-SDV 2022: Extracting information from tables in documents Holger Keibel (K...
AI-SDV 2022: Extracting information from tables in documents Holger Keibel (K...
AI-SDV 2022: Scientific publishing in the age of data mining and artificial i...
AI-SDV 2022: Scientific publishing in the age of data mining and artificial i...
AI-SDV 2022: AI developments and usability Linus Wretblad (IPscreener / Uppdr...
AI-SDV 2022: AI developments and usability Linus Wretblad (IPscreener / Uppdr...
AI-SDV 2022: Where’s the one about…? Looney Tunes® Revisited Jay Ven Eman (CE...
AI-SDV 2022: Where’s the one about…? Looney Tunes® Revisited Jay Ven Eman (CE...
AI-SDV 2022: Possibilities and limitations of AI-boosted multi-categorization...
AI-SDV 2022: Possibilities and limitations of AI-boosted multi-categorization...
AI-SDV 2022: Big data analytics platform at Bayer – Turning bits into insight...
AI-SDV 2022: Big data analytics platform at Bayer – Turning bits into insight...
Recently uploaded
Should Repositories Participate in the Fediverse?
Presentation for OR2024 making the case that repositories could play a part in the "fediverse" of distributed social applications
制作原版1:1(Monash毕业证)莫纳什大学毕业证成绩单办理假
退学买莫纳什大学毕业证>【微信176555708】办理莫纳什大学毕业证成绩单【微信176555708】Monash毕业证成绩单Monash学历证书Monash文凭【Monash毕业套号文凭网认证莫纳什大学毕业证成绩单】【哪里买莫纳什大学毕业证文凭Monash成绩学校快递邮寄信封】【开版莫纳什大学文凭】Monash留信认证本科硕士学历认证1:1完美还原海外各大学毕业材料上的工艺：水印阴影底纹钢印LOGO烫金烫银LOGO烫金烫银复合重叠。文字图案浮雕激光镭射紫外荧光温感复印防伪。
可办理以下真实莫纳什大学存档留学生信息存档认证：
1莫纳什大学真实留信网认证（网上可查永久存档无风险百分百成功入库）；
2真实教育部认证（留服）等一切高仿或者真实可查认证服务（暂时不可办理）；
3购买英美真实学籍（不用正常就读直接出学历）；
4英美一年硕士保毕业证项目（保录取学校挂名不用正常就读保毕业）
留学本科/硕士毕业证书成绩单制作流程：
1客户提供办理信息：姓名生日专业学位毕业时间等（如信息不确定可以咨询顾问：我们有专业老师帮你查询莫纳什大学莫纳什大学毕业证offer）；
2开始安排制作莫纳什大学毕业证成绩单电子图；
3莫纳什大学毕业证成绩单电子版做好以后发送给您确认；
4莫纳什大学毕业证成绩单电子版您确认信息无误之后安排制作成品；
5莫纳什大学成品做好拍照或者视频给您确认；
6快递给客户（国内顺丰国外DHLUPS等快读邮寄）
— — — — — — — — — — — 《文凭顾问微信：176555708》
留学学历(UoA毕业证)奥克兰大学毕业证成绩单官方原版办理
制做办理奥克兰大学学历证书＜176555708微信＞【毕业证明信-推荐信做学费单＞【微信176555708】【制作UoA毕业证文凭认证奥克兰大学毕业证成绩单购买】【UoA毕业证书】{奥克兰大学文凭购买}】成绩单，录取通知书，Offer，在读证明，雅思托福成绩单，真实大使馆教育部认证，回国人员证明，＞【制作UoA毕业证文凭认证奥克兰大学毕业证成绩单购买】【UoA毕业证书】{奥克兰大学文凭购买}留信网认证。
奥克兰大学学历证书＜微信176555708（一对一服务包括毕业院长签字,专业课程,学位类型,专业或教育领域,以及毕业日期.不要忽视这些细节.这两份文件同样重要!毕业证成绩单文凭留信网学历认证！）[留学文凭学历认证(留信认证使馆认证)奥克兰大学毕业证成绩单毕业证证书大学Offer请假条成绩单语言证书国际回国人员证明高仿教育部认证申请学校等一切高仿或者真实可查认证服务。
多年留学服务公司,拥有海外样板无数能完美1:1还原海外各国大学degreeDiplomaTranscripts等毕业材料。海外大学毕业材料都有哪些工艺呢？工艺难度主要由：烫金.钢印.底纹.水印.防伪光标.热敏防伪等等组成。而且我们每天都在更新海外文凭的样板以求所有同学都能享受到完美的品质服务。
国外毕业证学位证成绩单办理方法：
1客户提供办理奥克兰大学奥克兰大学硕士毕业证成绩单信息：姓名生日专业学位毕业时间等（如信息不确定可以咨询顾问：我们有专业老师帮你查询）；
2开始安排制作毕业证成绩单电子图；
3毕业证成绩单电子版做好以后发送给您确认；
4毕业证成绩单电子版您确认信息无误之后安排制作成品；
5成品做好拍照或者视频给您确认；
6快递给客户（国内顺丰国外DHLUPS等快读邮寄）
— — — — 我们是挂科和未毕业同学们的福音我们是实体公司精益求精的工艺！ — — — -
一真实留信认证的作用(私企外企荣誉的见证):
1：该专业认证可证明留学生真实留学身份同时对留学生所学专业等级给予评定。
2：国家专业人才认证中心颁发入库证书这个入网证书并且可以归档到地方。
3：凡是获得留信网入网的信息将会逐步更新到个人身份内将在公安部网内查询个人身份证信息后同步读取人才网入库信息。
4：个人职称评审加20分个人信誉贷款加10分。
5：在国家人才网主办的全国网络招聘大会中纳入资料供国家500强等高端企业选择人才。
留学挂科(UofM毕业证)明尼苏达大学毕业证成绩单复刻办理
精仿办理明尼苏达大学学历证书＜176555708微信＞【毕业证明信-推荐信做学费单＞【微信176555708】【制作UofM毕业证文凭认证明尼苏达大学毕业证成绩单购买】【UofM毕业证书】{明尼苏达大学文凭购买}】成绩单，录取通知书，Offer，在读证明，雅思托福成绩单，真实大使馆教育部认证，回国人员证明，＞【制作UofM毕业证文凭认证明尼苏达大学毕业证成绩单购买】【UofM毕业证书】{明尼苏达大学文凭购买}留信网认证。
明尼苏达大学学历证书＜微信176555708（一对一服务包括毕业院长签字,专业课程,学位类型,专业或教育领域,以及毕业日期.不要忽视这些细节.这两份文件同样重要!毕业证成绩单文凭留信网学历认证！）（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
◆◆◆◆◆ — — — — — — — — 【留学教育】留学归国服务中心 — — — — — -◆◆◆◆◆
【主营项目】
一.毕业证【微信：176555708】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【微信：176555708】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分→ 【关于价格问题（保证一手价格）
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
学历顾问：微信：176555708
成绩单ps(UST毕业证)圣托马斯大学毕业证成绩单快速办理
一比一原版制作UST毕业证【微信176555708】圣托马斯大学毕业证书原版↑制作圣托马斯大学学历认证文凭办理圣托马斯大学留信网认证,留学回国办理毕业证成绩单文凭学历认证【微信176555708】专业为海外学子办理毕业证成绩单、文凭制作，学历仿制，回国人员证明、做文凭，研究生、本科、硕士学历认证、留信认证、结业证、学位证书样本、美国教育部认证百分百真实存档可查】（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
◆◆◆◆◆ — — — — — — — — 【留学教育】留学归国服务中心 — — — — — -◆◆◆◆◆
【主营项目】
一.毕业证【微信：176555708】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【微信：176555708】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分→ 【关于价格问题（保证一手价格）
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
学历顾问：微信：176555708
不能毕业如何获得(USYD毕业证)悉尼大学毕业证成绩单一比一原版制作
挂科购买☀【悉尼大学毕业证购买】【微信176555708】【USYD毕业证模板办理】加拿大文凭、本科、硕士、研究生学历都可以做,二、业务范围：
★、全套服务：毕业证、成绩单、化学专业毕业证书伪造【悉尼大学大学毕业证】微信176555708【USYD学位证书购买】◆◆◆◆◆ — — — 归国服务中心 — — -◆◆◆◆◆
【主营项目】
一.毕业证、成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
国外毕业证、学位证、成绩单办理流程：
1、客户提供办理信息：姓名、生日、专业、学位、毕业时间等（如信息不确定可以咨询顾问：【微信176555708】我们有专业老师帮你查询）；
2、开始安排制作毕业证、成绩单电子图；
3、毕业证、成绩单电子版做好以后发送给您确认；
4、毕业证、成绩单电子版您确认信息无误之后安排制作成品；
5、成品做好拍照或者视频给您确认；
6、快递给客户（国内顺丰，国外DHL、UPS等快读邮寄）。
专业服务，请勿犹豫联系我！本公司是留学创业和海归创业者们的桥梁。一次办理，终生受用，一步到位，高效服务。详情请在线咨询办理,欢迎有诚意办理的客户咨询!洽谈。
◆招聘代理：本公司诚聘英国、加拿大、澳洲、新西兰、加拿大、法国、德国、新加坡各地代理人员，如果你有业余时间，有兴趣就请联系我们咨询【微信176555708】
没文凭怎么找工作。让您回国发展信心十足！
★、真实教育部学历学位认证；（一对一专业服务，可全程监控跟踪进度）
★、真实使馆认证，可以通过大使馆查询确认；（即教育部留服认证，不成功不收费）
★、毕业证、成绩单等材料，从防伪到印刷、水印到钢印烫金，高精仿度都是跟学校原版100%相同的；（敬请放心使用）
★、可以提供钢印、水印、烫金、激光防伪、凹凸版、最新版的毕业证、百分之百让您绝对满意、
★、印刷，DHL快递毕业证、成绩单7个工作日，真实大使馆教育部认证1个月。为了达到高水准高效率。
Ready to Unlock the Power of Blockchain!
Imagine a world where data flows freely, yet remains secure. A world where trust is built into the fabric of every transaction. This is the promise of blockchain, a revolutionary technology poised to reshape our digital landscape.
Toptal Tech is at the forefront of this innovation, connecting you with the brightest minds in blockchain development. Together, we can unlock the potential of this transformative technology, building a future of transparency, security, and endless possibilities.
一比一原版(USYD毕业证)悉尼大学毕业证如何办理
USYD硕士毕业证成绩单【微信95270640】《如何办理悉尼大学毕业证认证》【办证Q微信95270640】《悉尼大学文凭毕业证制作》《USYD学历学位证书哪里买》办理悉尼大学学位证书扫描件、办理悉尼大学雅思证书！
国际留学归国服务中心《如何办悉尼大学毕业证认证》《USYD学位证书扫描件哪里买》实体公司，注册经营，行业标杆，精益求精！
如果您是以下情况，我们都能竭诚为您解决实际问题：【公司采用定金+余款的付款流程，以最大化保障您的利益，让您放心无忧】
1、在校期间，因各种原因未能顺利毕业，拿不到官方毕业证+微信95270640
2、面对父母的压力，希望尽快拿到悉尼大学悉尼大学毕业证offer；
3、不清楚流程以及材料该如何准备悉尼大学悉尼大学毕业证offer；
4、回国时间很长，忘记办理；
5、回国马上就要找工作，办给用人单位看；
6、企事业单位必须要求办理的；
面向美国乔治城大学毕业留学生提供以下服务:
【★悉尼大学悉尼大学毕业证offer毕业证、成绩单等全套材料，从防伪到印刷，从水印到钢印烫金，与学校100%相同】
【★真实使馆认证（留学人员回国证明），使馆存档可通过大使馆查询确认】
【★真实教育部认证，教育部存档，教育部留服网站可查】
【★真实留信认证，留信网入库存档，可查悉尼大学悉尼大学毕业证offer】
我们从事工作十余年的有着丰富经验的业务顾问，熟悉海外各国大学的学制及教育体系，并且以挂科生解决毕业材料不全问题为基础，为客户量身定制1对1方案，未能毕业的回国留学生成功搭建回国顺利发展所需的桥梁。我们一直努力以高品质的教育为起点，以诚信、专业、高效、创新作为一切的行动宗旨，始终把“诚信为主、质量为本、客户第一”作为我们全部工作的出发点和归宿点。同时为海内外留学生提供大学毕业证购买、补办成绩单及各类分数修改等服务；归国认证方面，提供《留信网入库》申请、《国外学历学位认证》申请以及真实学籍办理等服务，帮助众多莘莘学子实现了一个又一个梦想。
专业服务，请勿犹豫联系我
如果您真实毕业回国，对于学历认证无从下手，请联系我，我们免费帮您递交
诚招代理：本公司诚聘当地代理人员，如果你有业余时间，或者你有同学朋友需要，有兴趣就请联系我
你赢我赢，共创双赢
你做代理，可以帮助悉尼大学同学朋友
你做代理，可以拯救悉尼大学失足青年
你做代理，可以挽救悉尼大学一个个人才
你做代理，你将是别人人生悉尼大学的转折点
你做代理，可以改变自己，改变他人，给他人和自己一个机会过暑假的小学生快乐的日子总是过得飞快山娃尚未完全认清那几位小朋友时他们却一个接一个地回家了山娃这时才恍然发现二个月的暑假已转到了尽头他的城市生活也将划上一个不很圆满的句号了值得庆幸的是山娃早记下了他们的学校和联系方式说也奇怪在山娃离城的头一天父亲居然请假陪山娃耍了一天那一天父亲陪着山娃辗转长隆水上乐园疯了一整天水上漂流高空冲浪看大马戏大凡里面有的父亲都带着他去疯一把山娃算了算这一次足足花了老爸元很
办理毕业证(UPenn毕业证)宾夕法尼亚大学毕业证成绩单快速办理
官方原版办理宾夕法尼亚大学毕业证【微信176555708】学历认证怎么做：原版仿制宾夕法尼亚大学电子版成绩单毕业证认证【宾夕法尼亚大学毕业证成绩单】、宾夕法尼亚大学文凭证书成绩单复刻offer录取通知书、购买UPenn圣力嘉学院本科毕业证、【宾夕法尼亚大学毕业证办理UPenn毕业证书哪里买】、宾夕法尼亚大学 Offer在线办理UPenn Offer宾夕法尼亚大学Bachloer Degree。（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
◆◆◆◆◆ — — — — — — — — 【留学教育】留学归国服务中心 — — — — — -◆◆◆◆◆
【主营项目】
一.毕业证【微信：176555708】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【微信：176555708】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分→ 【关于价格问题（保证一手价格）
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
学历顾问：微信：176555708
办理毕业证(NYU毕业证)纽约大学毕业证成绩单官方原版办理
退学买【纽约大学毕业证认证】【办证微信176555708】【纽约大学文凭毕业证制作】【NYU学历学位证书哪里买】办理纽约大学学位证书扫描件、办理纽约大学雅思证书！
国际留学归国服务中心【如何办纽约大学毕业证认证】【NYU学位证书扫描件哪里买】实体公司，注册经营，行业标杆，精益求精！（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
◆◆◆◆◆ — — — — — — — — 【留学教育】留学归国服务中心 — — — — — -◆◆◆◆◆
【主营项目】
一.毕业证【微信：176555708】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【微信：176555708】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分→ 【关于价格问题（保证一手价格）
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
学历顾问：微信：176555708
存档可查的(USC毕业证)南加利福尼亚大学毕业证成绩单制做办理
精仿办理南加利福尼亚大学毕业证成绩单（【微信176555708】）毕业证学历认证OFFER专卖国外文凭学历学位证书办理澳洲文凭|澳洲毕业证,澳洲学历认证,澳洲成绩单【微信176555708】 澳洲offer,教育部学历认证及使馆认证永久可查 ,国外毕业证|国外学历认证,国外学历文凭证书 USC毕业证，USC毕业证，USC毕业证，USC毕业证，USC毕业证，USC毕业证【微信176555708】，USC毕业证，专业为留学生办理毕业证、成绩单、使馆留学回国人员证明、教育部学历学位认证、录取通知书、Offer、（留信学历认证永久存档查询）采用学校原版纸张、特殊工艺完全按照原版一比一制作（包括：隐形水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠，文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备，十五年致力于帮助留学生解决难题，业务范围有加拿大、英国、澳洲、韩国、美国、新加坡，新西兰等学历材料，包您满意。
◆◆◆◆◆ — — — — — — — — 【留学教育】留学归国服务中心 — — — — — -◆◆◆◆◆
【主营项目】
一.毕业证【微信：176555708】成绩单、使馆认证、教育部认证、雅思托福成绩单、学生卡等！
二.真实使馆公证(即留学回国人员证明,不成功不收费)
三.真实教育部学历学位认证（教育部存档！教育部留服网站永久可查）
四.办理各国各大学文凭(一对一专业服务,可全程监控跟踪进度)
如果您处于以下几种情况：
◇在校期间，因各种原因未能顺利毕业……拿不到官方毕业证【微信：176555708】
◇面对父母的压力，希望尽快拿到；
◇不清楚认证流程以及材料该如何准备；
◇回国时间很长，忘记办理；
◇回国马上就要找工作，办给用人单位看；
◇企事业单位必须要求办理的
◇需要报考公务员、购买免税车、落转户口
◇申请留学生创业基金
留信网认证的作用:
1:该专业认证可证明留学生真实身份
2:同时对留学生所学专业登记给予评定
3:国家专业人才认证中心颁发入库证书
4:这个认证书并且可以归档倒地方
5:凡事获得留信网入网的信息将会逐步更新到个人身份内，将在公安局网内查询个人身份证信息后，同步读取人才网入库信息
6:个人职称评审加20分
7:个人信誉贷款加10分→ 【关于价格问题（保证一手价格）
8:在国家人才网主办的国家网络招聘大会中纳入资料，供国家高端企业选择人才
选择实体注册公司办理，更放心，更安全！我们的承诺：可来公司面谈，可签订合同，会陪同客户一起到教育部认证窗口递交认证材料，客户在教育部官方认证查询网站查询到认证通过结果后付款，不成功不收费！
我们所定的价格是非常合理的，而且我们现在做得单子大多数都是代理和回头客户介绍的所以一般现在有新的单子 我给客户的都是第一手的代理价格，因为我想坦诚对待大家 不想跟大家在价格方面浪费时间
对于老客户或者被老客户介绍过来的朋友，我们都会适当给一些优惠。
学历顾问：微信：176555708
学位认证网(DU毕业证)迪肯大学毕业证成绩单一比一原版制作
24小时办理【微信176555708】【毕业证明信-推荐信做学费单】成绩单，录取通知书，Offer，在读证明，雅思托福成绩单，真实大使馆教育部认证，回国人员证明，留信网认证。网上存档永久可查！
degree，Transcripts（一对一服务包括毕业院长签字,专业课程,学位类型,专业或教育领域,以及毕业日期.不要忽视这些细节.这两份文件同样重要!毕业证成绩单文凭留信网学历认证！）如果您是以下情况，我们都能竭诚为您解决实际问题：【公司采用定金+余款的付款流程，以最大化保障您的利益，让您放心无忧】
1、在校期间，因各种原因未能顺利毕业，拿不到官方迪肯大学毕业证+微信176555708；
2、面对父母的压力，希望尽快拿到；
3、不清楚流程以及材料该如何准备；
4、回国时间很长，忘记办理毕业证丢失 学历认证《迪肯大学毕业证》微信176555708《DU学位证书购买》
学位证书验证；
5、回国马上就要找工作，办给用人单位看；
6、企事业单位必须要求办理学历证书 英文《迪肯大学毕业证》微信176555708《DU学位证书购买》
本科毕业证书扫描件的；
微信176555708面向迪肯大学毕业留学生提供以下服务:
【★迪肯大学毕业证、成绩单等全套材料，从防伪到印刷，从水印到钢印烫金，与学校100%相同】
【★大学学历 硕士学位《迪肯大学毕业证》微信176555708《DU学位证书购买》
硕士毕业证】
【★毕业证书范本】
【★真实留信认证，留信网入库存档，可查】
主营项目：
a.办理海外毕业证认证《迪肯大学毕业证》微信176555708《DU学位证书购买》
学位证书英文版，改成绩单，Offer、在读证明、学生卡、信封、证明信等全套材料，从防伪到印刷，从水印到钢印烫金，高精仿度跟学校原版100%相同.
b.真实使馆认证（即留学人员回国证明），使馆存档可通过大使馆查询确认.
c.真实教育部国外学历学位认证，教育部存档，教育部留服网站100%可查.
d.留信网认证，国家专业人才认证中心颁发入库证书，留信网存档可查.
e.招聘中介代理：本公司诚聘各地代理人员以及留学生，如果你有业余时间，有兴趣就请联系我们，我们会给到您的回报！期待您的加盟：一朝办理，终身受益（本信息长期有效）互惠互利，为广大海内外学子及有需要的人士在事业上跨过这道门槛！
【业务选择办理准则】
1.如果您只是为了的应付父母亲戚朋友看下迪肯大学毕业证，那么办理一份学位即可
2.如果您是为了回国找工作，只是进私营企业或者外企，那么办理一份多大学历认证有时间限制吗《迪肯大学毕业证》微信176555708《DU学位证书购买》
毕业证丢失补办即可，因为私营企业或者外企是不能查询学位真假的！
3.如果您是要进国企银行事业单位考公务员等就需办理真实学历认证！
诚招代理：本公司诚聘当地合作代理人员，如果你有业余时间，有兴趣就请联系我们。
重新申请毕业证书(RMIT毕业证)皇家墨尔本理工大学毕业证成绩单精仿办理
不能毕业办理【RMIT毕业证【微信176555708】皇家墨尔本理工大学文凭学历】【微信176555708】【皇家墨尔本理工大学文凭学历证书】【皇家墨尔本理工大学毕业证书与成绩单样本图片】毕业证书补办 Fake Degree做学费单【毕业证明信-推荐信】成绩单，录取通知书，Offer，在读证明，雅思托福成绩单，真实大使馆教育部认证，回国人员证明，留信网认证。网上存档永久可查！全套服务：皇家墨尔本理工大学皇家墨尔本理工大学本科学位证成绩单真实回国人员证明 #真实教育部认证。让您回国发展信心十足#铸就十年品质！信誉！实体公司！可以视频看办公环境样板如需办理真实可查可以先到公司面谈勿轻信小中介黑作坊！
可以提供皇家墨尔本理工大学钢印 #水印 #烫金 #激光防伪 #凹凸版 #最新版的毕业证 #百分之百让您绝对满意
印刷DHL快递毕业证 #成绩单7个工作日真实大使馆教育部认证1个月。为了达到高水准高效率
请您先以qq或微信的方式对我们的服务进行了解后如果有皇家墨尔本理工大学皇家墨尔本理工大学本科学位证成绩单帮助再进行电话咨询。
国外毕业证学位证成绩单如何办理：
1客户提供办理信息：姓名生日专业学位毕业时间等（如信息不确定可以咨询顾问：我们有专业老师帮你查询）；
2开始安排制作皇家墨尔本理工大学毕业证成绩单电子图；
3毕业证成绩单电子版做好以后发送给您确认；
4毕业证成绩单电子版您确认信息无误之后安排制作成品；
5成品做好拍照或者视频给您确认；
6快递给客户（国内顺丰国外DHLUPS等快读邮寄）。
可查真实(Monash毕业证)西澳大学毕业证成绩单退学买
办理假西澳大学毕业证【微信176555708】购买,办理Monash成绩单,Monash毕业证制作【微信176555708】【西澳大学毕业证】，Monash毕业证购买，Monash学位证，西澳大学学位证【Monash成绩单制作】【Monash毕业证文凭 Monash本科 澳洲学历认证原版制作【diploma certificate degree transcript 】【留信网认证，本科，硕士，海归，博士，排名，成绩单】代办国外（海外）澳洲、韩国、加拿大、新西兰等各大学毕业证。 ?我们对海外大学及学院的毕业证成绩单所使用的材料，尺寸大小，防伪结构（包括：水印，阴影底纹，钢印LOGO烫金烫银，LOGO烫金烫银复合重叠。 文字图案浮雕，激光镭射，紫外荧光，温感，复印防伪）都有原版本文凭对照。#一整套西澳大学文凭证件办理#—包含西澳大学西澳大学毕业证成绩单学历认证|使馆认证|归国人员证明|教育部认证|留信网认证永远存档教育部学历学位认证查询办理国外文凭国外学历学位认证#我们提供全套办理服务。
一整套留学文凭证件服务：
一：西澳大学西澳大学毕业证成绩单毕业证 #成绩单等全套材料从防伪到印刷水印底纹到钢印烫金
二：真实使馆认证（留学人员回国证明）使馆存档
三：真实教育部认证教育部存档教育部留服网站永久可查
四：留信认证留学生信息网站永久可查
国外毕业证学位证成绩单办理方法：
1客户提供办理西澳大学西澳大学毕业证成绩单信息：姓名生日专业学位毕业时间等（如信息不确定可以咨询顾问：我们有专业老师帮你查询）；
2开始安排制作毕业证成绩单电子图；
3毕业证成绩单电子版做好以后发送给您确认；
4毕业证成绩单电子版您确认信息无误之后安排制作成品；
5成品做好拍照或者视频给您确认；
6快递给客户（国内顺丰国外DHLUPS等快读邮寄）。
教育部文凭学历认证认证的用途：
如果您计划在国内发展那么办理国内教育部认证是必不可少的。事业性用人单位如银行国企公务员在您应聘时都会需要您提供这个认证。其他私营 #外企企业无需提供！办理教育部认证所需资料众多且烦琐所有材料您都必须提供原件我们凭借丰富的经验帮您快速整合材料让您少走弯路。
实体公司专业为您服务如有需要请联系我: 微信176555708
制作毕业证书(ANU毕业证)莫纳什大学毕业证成绩单官方原版办理
在线办理莫纳什大学毕业证【微信：176555708】(ANU毕业证书)成绩单学位证【微信：176555708】，留信认证（真实可查，永久存档）纸张工艺/offer、雅思、外壳等材料/诚信可靠,可直接看成品样本，帮您解决无法毕业带来的各种难题！外壳，原版制作，诚信可靠，可直接看成品样本。行业标杆！精益求精，诚心合作，真诚制作！多年品质 ,按需精细制作，24小时接单,全套进口原装设备。十五年致力于帮助留学生解决难题，包您满意。#一整套莫纳什大学文凭证件办理#—包含莫纳什大学莫纳什大学毕业证文凭证书学历认证|使馆认证|归国人员证明|教育部认证|留信网认证永远存档教育部学历学位认证查询办理国外文凭国外学历学位认证#我们提供全套办理服务。
一整套留学文凭证件服务：
一：莫纳什大学莫纳什大学毕业证文凭证书毕业证 #成绩单等全套材料从防伪到印刷水印底纹到钢印烫金
二：真实使馆认证（留学人员回国证明）使馆存档
三：真实教育部认证教育部存档教育部留服网站永久可查
四：留信认证留学生信息网站永久可查
国外毕业证学位证成绩单办理方法：
1客户提供办理莫纳什大学莫纳什大学毕业证文凭证书信息：姓名生日专业学位毕业时间等（如信息不确定可以咨询顾问：我们有专业老师帮你查询）；
2开始安排制作毕业证成绩单电子图；
3毕业证成绩单电子版做好以后发送给您确认；
4毕业证成绩单电子版您确认信息无误之后安排制作成品；
5成品做好拍照或者视频给您确认；
6快递给客户（国内顺丰国外DHLUPS等快读邮寄）。
教育部文凭学历认证认证的用途：
如果您计划在国内发展那么办理国内教育部认证是必不可少的。事业性用人单位如银行国企公务员在您应聘时都会需要您提供这个认证。其他私营 #外企企业无需提供！办理教育部认证所需资料众多且烦琐所有材料您都必须提供原件我们凭借丰富的经验帮您快速整合材料让您少走弯路。
实体公司专业为您服务如有需要请联系我: 微信176555708
Recently uploaded (20)
Patentable Subject Matter” nurture or neglect innovation? A case study based rational analysis
- 1. NURTURE NEGLECT Dara Ajay PhD, LLM Cheers Interactive. II-PIC: International Indian Patent Information Conference for Patent Information Professionals Disclaimer: The views and opinions expressed in this presentation are those of the authors and do not necessarily reflect the official policy or position of any governing body including Cheers Interactive.
- 2. ❖Some of the related articles and sections from Patent Act and TRIPS India under Section 3 USA under Section 101 of Title 35 U.S.C. Australia under section 18 Malaysia under Section 13 China Article 25 European Patent Convention Article 52, 53 TRIPS Article 27.2 2 ➢what are not patentable • Frivolous/ obvious inventions • Contrary to well established natural laws • Contrary to public order or morality • Mere discovery of a scientific principle • Formulation of an abstract theory • Discovery of any living thing or non–living substance occurring in nature • Process for medicinal, surgical, curative, prophylactic, diagnostic, therapeutic or other treatment • Method of agriculture or horticulture • Plants & animals in whole or any part thereof • Method of performing mental act or method of playing game • Mathematical method or business method or algorithms or computer programme per se http://www.ipindia.nic.in/writereaddata/Portal/IPOAct/1_31_1_patent-act-1970-11march2015.pdf
- 3. 3 ▪ The landmark case for Gene patenting is the Myriad Genetics, Inc., ▪ Developed a diagnostic kit which detect gene sequence BRCA1 and BRCA2 genes ▪ Unfortunately, Myriads high price (USD $3000-4000) https://en.wikipedia.org/wiki/BRCA_mutation
- 4. 4 13th June 2013, US5747282, US5837492, US5693473, US5709999, US5710001, US5753441 and US6033857 Invalidate the claims of isolated gene under 35 U.S.C. §101 5 September 2014, AU686004 based on manner of manufacture indicating DNA and RNA as natural products and invention as artificial state of affairs November 2008 EP0705902, EP0705903, EP0699754, EP0785216 “natural law or natural product but ultimately whether it is for a mere discovery”
- 5. 5 1. In Myriad case plaintiff failed to identify the anticompetitive practices 2. Weather gene isolation is mere discovery or invention ? BRCA1-17q21 BRCA2- 13q12.3 http://www.scinexx.de/dossier-bild-15-6-21210.html
- 6. 6 CANCER The Cancer Statistics ✓~1.6 million new cases got registered with 35% dead rate ✓~ 14.1 million new cases reported with 8.2 million deaths ✓2020 prediction ~ 15 million new cases diagnosed, 12 million deaths ✓GLOBOCAN, 2025 estimation >19.3 million new cancer cases every year
- 9. Feng Zhang @ Broad/MIT Jennifer Doudna @ Berkeley /HHMI CRISPR/ Cas9 Emmanuelle Charpentie @ Helmholtz MIMS/MHH 9http://www.brandeis.edu/now/2014/october/gabbay-award-2104.html http://blogs.plos.org/synbio/2017/10/05/when-will-crispr-get-a-nobel-prize/ “The discovery’s impact on medicine could be huge. Imagine being able to delete BRCA 1, the closely linked to breast cancer, or the that causes Huntington’s disease. The CRISPR/cas9 system puts scientists one step closer to being able to cure genetic disorders” CRISPRs, first observed in the 1980s 2014 Breakthrough Prize in Life Sciences ($3 million) 2015 Massry Prize ( $40,000) 2016 Canada Gairdner International Award ($100,000) 2016 Tang Prize in Biopharmaceutical Science ($1.34 million cash and $1.67 million grant shared) 2016 Warren Alpert Foundation Prize ($500,000). 2017 Albany Medical Center Prize in Medicine and Biomedical Research ($500,000)
- 10. 10
- 11. ✓ Patentable subject matter should Not Predetermine but evolve with the technology today ✓ Invalidating Gene technologies based on patentable subject matter have directly and indirectly adverse effect on global health care innovation ✓ Therefore, Gene technology should be excluded from patentable subject matter 1111
- 12. 12